cancer_type,TMB (FMOne mutation burden per MB),Neoantigen burden per MB,Immune phenotype,response_label,user_question,full_query
BLCA,18.0,4.68627451,excluded,NR,"A white male patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 18.0. Based on these findings, what is the likelihood of response to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 18.0. Based on these findings, what is the likelihood of response to Atezolizumab therapy? Evaluate the transcriptomic profile of the patient’s tumor microenvironment, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Please provide evidence-based rationale to determine whether the patient is likely to respond to the treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0257bb-ar-0257bbb.pkl. "
BLCA,1.0,0.31372549,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden (TMB) of 1.0 and available transcriptomic data from the tumor immune microenvironment, what is the likelihood of a clinical response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden (TMB) of 1.0 and available transcriptomic data from the tumor immune microenvironment, what is the likelihood of a clinical response to Atezolizumab therapy? Review the gene expression data from the patient’s tumor microenvironment, specifically examining markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Based on this analysis and current evidence, determine the likelihood of the patient responding to the proposed treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/025b45-ar-025b45c.pkl. "
BLCA,44.0,6.196078431,inflamed,NR,"For a white female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 44.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, is there evidence to suggest that she is likely to respond to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 44.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, is there evidence to suggest that she is likely to respond to Atezolizumab therapy? Please analyze the gene expression profile from the patient’s tumor microenvironment, specifically focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, based on the evidence available, evaluate the patient’s likely response to the proposed treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/032c64-ar-032c642.pkl. "
BLCA,2.0,1.470588235,excluded,NR,"In a white female patient with bladder urothelial carcinoma and a lymph node biopsy showing a transcriptomic profile of the tumor immune microenvironment along with a TMB of 2.0, how likely is she to benefit from Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma and a lymph node biopsy showing a transcriptomic profile of the tumor immune microenvironment along with a TMB of 2.0, how likely is she to benefit from Atezolizumab therapy? Review the gene expression data from the patient’s tumor microenvironment, giving particular attention to markers of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, using current evidence, determine the patient’s anticipated response to the treatment strategy proposed.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0571f1-ar-0571f17.pkl. "
BLCA,8.0,,inflamed,R,"For a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 8.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, does the molecular data indicate a likely response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 8.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, does the molecular data indicate a likely response to Atezolizumab therapy? Evaluate the gene expression profile in the tumor microenvironment, with a specific focus on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, using the most up-to-date evidence, predict the patient’s likely response to the proposed treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/065890-ar-0658907.pkl. "
BLCA,6.0,0.921568627,,R,"In a white female patient diagnosed with bladder urothelial carcinoma, with available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden (TMB) of 6.0, what is the anticipated response to Atezolizumab therapy?","In a white female patient diagnosed with bladder urothelial carcinoma, with available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden (TMB) of 6.0, what is the anticipated response to Atezolizumab therapy? Assess the gene expression within the tumor microenvironment by focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, review current research to estimate how the patient might respond to the proposed treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0684af-ar-0684af7.pkl. "
BLCA,11.0,0.745098039,excluded,R,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a kidney biopsy shows a tumor mutation burden of 11. Based on these findings, is it likely that he would respond favorably to atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a kidney biopsy shows a tumor mutation burden of 11. Based on these findings, is it likely that he would respond favorably to atezolizumab therapy? Evaluate the gene expression patterns in the tumor microenvironment by specifically analyzing markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, consult current literature to predict the patient's likely response to the proposed treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/075e03-ar-075e037.pkl. "
BLCA,18.0,2.117647059,excluded,R,"For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled via transcriptomics from a bladder biopsy and with a reported tumor mutational burden of 18.0, is there evidence to suggest that he would respond favorably to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled via transcriptomics from a bladder biopsy and with a reported tumor mutational burden of 18.0, is there evidence to suggest that he would respond favorably to atezolizumab therapy? Analyze the gene expression patterns in the tumor environment by focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, review the latest literature to assess how the patient is likely to respond to the proposed treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/07a93a-ar-07a93a2.pkl. "
BLCA,,,excluded,NR,"For a White female patient with bladder urothelial carcinoma, based on the transcriptomic profiling of her tumor’s immune microenvironment, how likely is she to respond to atezolizumab therapy given that her tumor mutation burden data is unavailable?","For a White female patient with bladder urothelial carcinoma, based on the transcriptomic profiling of her tumor’s immune microenvironment, how likely is she to respond to atezolizumab therapy given that her tumor mutation burden data is unavailable? Review the gene expression within the tumor microenvironment, specifically examining markers that identify exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After this analysis, consult the most recent literature to evaluate how these findings might inform predictions about the patient’s response to the proposed treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/08cce2-ar-08cce2f.pkl. "
BLCA,,,inflamed,NR,"I have a white male patient with bladder urothelial carcinoma. The transcriptomic analysis of his tumor immune microenvironment was performed using a nan biopsy, and his tumor mutation burden is reported as nan. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. The transcriptomic analysis of his tumor immune microenvironment was performed using a nan biopsy, and his tumor mutation burden is reported as nan. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy? Examine gene expression in the tumor microenvironment with an emphasis on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, review the latest research to determine how these findings could guide predictions about the patient’s response to the recommended treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/09c84e-ar-09c84ec.pkl. "
BLCA,2.0,0.215686275,,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled transcriptomically from a kidney biopsy. Given a tumor mutational burden (TMB) of 2.0, what is the likelihood that he will respond favorably to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled transcriptomically from a kidney biopsy. Given a tumor mutational burden (TMB) of 2.0, what is the likelihood that he will respond favorably to Atezolizumab therapy? Review the gene expression profile within the tumor microenvironment, specifically targeting markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, analyze recent research to assess how these molecular features might inform predictions regarding the patient's response to the proposed treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0a0f2b-ar-0a0f2ba.pkl. "
BLCA,8.0,1.274509804,excluded,NR,"My white male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden (TMB) of 8.0 and transcriptomic profiling data available from his tumor immune microenvironment biopsy. Given these findings, can we expect a favorable response to Atezolizumab therapy?","My white male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden (TMB) of 8.0 and transcriptomic profiling data available from his tumor immune microenvironment biopsy. Given these findings, can we expect a favorable response to Atezolizumab therapy? Examine the tumor microenvironment’s gene expression profile, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate findings from recent studies to evaluate how these molecular markers may predict the patient’s response to the treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0a7c20-ar-0a7c209.pkl. "
BLCA,,,,NR,"I have a white female patient with bladder urothelial carcinoma, and we obtained a transcriptomic profile of her tumor immune microenvironment from a lymph node biopsy. Her tumor mutation burden (TMB) is not available (nan). Based on these findings, is there any indication that she might respond to Atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma, and we obtained a transcriptomic profile of her tumor immune microenvironment from a lymph node biopsy. Her tumor mutation burden (TMB) is not available (nan). Based on these findings, is there any indication that she might respond to Atezolizumab therapy? Review the gene expression profile of the tumor microenvironment, specifically targeting markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, incorporate recent research findings to assess how these molecular indicators might forecast the patient’s response to the prescribed treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0bdb34-ar-0bdb342.pkl. "
BLCA,9.0,,excluded,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy shows a tumor mutation burden of 9.0. Based on these findings, is the patient likely to respond to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy shows a tumor mutation burden of 9.0. Based on these findings, is the patient likely to respond to Atezolizumab therapy? Analyze the tumor microenvironment's gene expression profile with a focus on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, review recent research to determine how these molecular indicators may predict the patient's response to the current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0ce9c9-ar-0ce9c98.pkl. "
BLCA,4.0,0.137254902,desert,NR,"For my white female patient with bladder urothelial carcinoma and a tumor mutational burden of 4.0, whose bladder biopsy provided a transcriptomic profile of the tumor immune microenvironment, what is the likelihood that she will respond to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma and a tumor mutational burden of 4.0, whose bladder biopsy provided a transcriptomic profile of the tumor immune microenvironment, what is the likelihood that she will respond to Atezolizumab therapy? Examine the gene expression profile of the tumor microenvironment, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Subsequently, review current research to evaluate how these molecular indicators may inform predictions regarding the patient's response to the existing treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0d855c-ar-0d855cf.pkl. "
BLCA,32.0,4.098039216,excluded,NR,"We are assessing a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 32.0 and a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy. Based on these findings, how likely is he to respond to Atezolizumab therapy?","We are assessing a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 32.0 and a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy. Based on these findings, how likely is he to respond to Atezolizumab therapy? Assess the tumor microenvironment’s gene expression profile with emphasis on markers of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, review the latest research to determine how these molecular indicators might help predict the patient’s response to the current treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0f956e-ar-0f956e7.pkl. "
BLCA,21.0,3.529411765,desert,NR,"In a White male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 21.0 and available transcriptomic data of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that he will respond to Atezolizumab therapy?","In a White male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 21.0 and available transcriptomic data of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that he will respond to Atezolizumab therapy? Evaluate the gene expression profile within the tumor microenvironment, focusing specifically on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Next, review current literature to understand how these molecular markers may predict the patient’s response to the ongoing treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/110501-ar-110501d.pkl. "
BLCA,10.0,1.078431373,inflamed,NR,"In a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 10.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, would you recommend Atezolizumab therapy based on these findings?","In a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 10.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, would you recommend Atezolizumab therapy based on these findings? Please assess the gene expression within the tumor microenvironment, paying particular attention to markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, review current literature to determine how these markers might predict the patient’s response to the ongoing treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/12502d-ar-12502d9.pkl. "
BLCA,38.0,6.68627451,desert,R,"We have a Caucasian male patient with bladder urothelial carcinoma. A transcriptomic profile of the tumor immune microenvironment from his bladder biopsy reveals a tumor mutation burden of 38.0. Based on these findings, can we predict his response to Atezolizumab therapy?","We have a Caucasian male patient with bladder urothelial carcinoma. A transcriptomic profile of the tumor immune microenvironment from his bladder biopsy reveals a tumor mutation burden of 38.0. Based on these findings, can we predict his response to Atezolizumab therapy? Evaluate gene expression in the tumor microenvironment, focusing specifically on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, conduct a review of the current literature to understand how these markers may serve as predictors of the patient’s response to their ongoing treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/149386-ar-1493861.pkl. "
BLCA,7.0,0.568627451,excluded,R,"Given a white female patient with bladder urothelial carcinoma and a tumor mutation burden of 7.0, and considering her tumor immune microenvironment profile from a bladder biopsy, what is the likelihood that she will respond favorably to Atezolizumab therapy?","Given a white female patient with bladder urothelial carcinoma and a tumor mutation burden of 7.0, and considering her tumor immune microenvironment profile from a bladder biopsy, what is the likelihood that she will respond favorably to Atezolizumab therapy? Assess the expression of genes within the tumor microenvironment, with particular attention to markers of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Next, review the current research to determine how these markers might predict the patient’s response to ongoing treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/14df63-ar-14df63a.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"For a white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden is 5.0. Based on these findings, would you expect the patient to benefit from Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden is 5.0. Based on these findings, would you expect the patient to benefit from Atezolizumab therapy? Evaluate gene expression in the tumor microenvironment by focusing specifically on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, examine current research to assess how these markers might help predict the patient’s response to ongoing treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/166a41-ar-166a419.pkl. "
BLCA,15.0,,desert,NR,"I have a white male patient with bladder urothelial carcinoma. His tumor immune microenvironment was profiled via transcriptomic analysis from a bladder biopsy, and his tumor mutational burden is 15.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. His tumor immune microenvironment was profiled via transcriptomic analysis from a bladder biopsy, and his tumor mutational burden is 15.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Assess gene expression within the tumor microenvironment by concentrating on markers that are indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, review recent literature to determine how these specific markers might predict the patient's response to their current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/180398-ar-1803982.pkl. "
BLCA,,0.215686275,excluded,NR,"A Caucasian male patient with Bladder Urothelial Carcinoma (BLCA) has a transcriptomic profile of his tumor immune microenvironment from a kidney biopsy, and his tumor mutational burden (TMB) is not evaluable. Based on these data, is it likely that he will respond to Atezolizumab therapy?","A Caucasian male patient with Bladder Urothelial Carcinoma (BLCA) has a transcriptomic profile of his tumor immune microenvironment from a kidney biopsy, and his tumor mutational burden (TMB) is not evaluable. Based on these data, is it likely that he will respond to Atezolizumab therapy? Evaluate the gene expression profiles in the tumor microenvironment, specifically targeting markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Afterward, review recent literature to determine how these markers might serve as predictors of the patient’s response to their current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/181b63-ar-181b638.pkl. "
BLCA,,,,NR,"In a Caucasian male patient with bladder urothelial carcinoma (BLCA), for whom we have a lung biopsy-derived transcriptomic profile of the tumor immune microenvironment and a TMB reported as 'nan', what are the implications for his potential response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma (BLCA), for whom we have a lung biopsy-derived transcriptomic profile of the tumor immune microenvironment and a TMB reported as 'nan', what are the implications for his potential response to Atezolizumab therapy? Perform a gene expression analysis of the tumor microenvironment, focusing on markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Next, review the latest studies to evaluate whether these markers can predict the patient’s response to their current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/187e05-ar-187e056.pkl. "
BLCA,18.0,2.039215686,excluded,NR,"Our Caucasian male patient has bladder urothelial carcinoma (BLCA). We obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, and his tumor mutation burden is 18.0. Based on these findings, is he likely to respond favorably to Atezolizumab therapy?","Our Caucasian male patient has bladder urothelial carcinoma (BLCA). We obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, and his tumor mutation burden is 18.0. Based on these findings, is he likely to respond favorably to Atezolizumab therapy? Conduct a gene expression profiling of the tumor microenvironment to assess markers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, review the current literature to determine whether these markers can reliably predict the patient's response to their ongoing treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18a4da-ar-18a4dab.pkl. "
BLCA,7.0,0.392156863,inflamed,NR,"For a Black or African American male patient with bladder urothelial carcinoma, whose ureter biopsy transcriptomic profiling of the tumor immune microenvironment indicates a TMB of 7.0, what is the likelihood that he will respond to atezolizumab therapy?","For a Black or African American male patient with bladder urothelial carcinoma, whose ureter biopsy transcriptomic profiling of the tumor immune microenvironment indicates a TMB of 7.0, what is the likelihood that he will respond to atezolizumab therapy? Perform a gene expression analysis of the tumor microenvironment, focusing on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, review existing scientific literature to determine if these markers reliably predict the patient's response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18b935-ar-18b9351.pkl. "
BLCA,19.0,1.803921569,,NR,"I have a white male patient with bladder urothelial carcinoma, a tumor mutational burden of 19.0, and transcriptomic data profiling the tumor immune microenvironment from a bladder biopsy. Based on these findings, can we expect a favorable response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma, a tumor mutational burden of 19.0, and transcriptomic data profiling the tumor immune microenvironment from a bladder biopsy. Based on these findings, can we expect a favorable response to Atezolizumab therapy? Conduct a detailed gene expression analysis of the tumor microenvironment targeting markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the results, review current scientific literature to evaluate whether these markers consistently predict the patient's response to their current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18bc10-ar-18bc107.pkl. "
BLCA,5.0,0.470588235,excluded,NR,"My white male patient has bladder urothelial carcinoma with a tumor mutational burden of 5.0. We also have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Considering these details, what is the likelihood that he will respond to Atezolizumab therapy?","My white male patient has bladder urothelial carcinoma with a tumor mutational burden of 5.0. We also have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Considering these details, what is the likelihood that he will respond to Atezolizumab therapy? Perform a comprehensive gene expression analysis of the tumor microenvironment with a focus on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have the results, review the latest scientific literature to determine if these markers are consistent predictors of the patient's response to their current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18be5b-ar-18be5b3.pkl. "
BLCA,5.0,0.431372549,excluded,NR,"For my white male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden (TMB) of 5.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the anticipated response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden (TMB) of 5.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the anticipated response to Atezolizumab therapy? Please conduct a detailed gene expression analysis of the tumor microenvironment, specifically targeting markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have obtained the results, review current scientific literature to evaluate whether these markers serve as reliable predictors of the patient's response to their current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/19fec8-ar-19fec8f.pkl. "
BLCA,8.0,1.176470588,excluded,NR,"A Caucasian male patient with bladder urothelial carcinoma has a tumor mutational burden of 8.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy. Based on these findings, is there evidence to suggest that the patient would respond favorably to atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a tumor mutational burden of 8.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy. Based on these findings, is there evidence to suggest that the patient would respond favorably to atezolizumab therapy? Please perform a comprehensive analysis of gene expression within the tumor microenvironment, with a focus on markers specific to exhausted and cytotoxic T cells, as well as monocytes and macrophages. Once you have the data, review current scientific literature to determine if these markers reliably predict the patient’s response to their ongoing treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1a87df-ar-1a87df7.pkl. "
BLCA,13.0,0.294117647,desert,NR,"My patient, a white female with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 13.0, has undergone transcriptomic profiling of the tumor immune microenvironment via a ureteral biopsy. Based on these findings, is Atezolizumab likely to be an effective treatment option?","My patient, a white female with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 13.0, has undergone transcriptomic profiling of the tumor immune microenvironment via a ureteral biopsy. Based on these findings, is Atezolizumab likely to be an effective treatment option? Please conduct a detailed gene expression analysis of the tumor microenvironment. Include in your evaluation markers that identify exhausted and cytotoxic T cells, as well as markers for monocytes and macrophages. Once you have the results, review the current scientific literature to assess whether these biomarkers reliably correlate with the patient’s response to their treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1ab1b2-ar-1ab1b28.pkl. "
BLCA,16.0,1.862745098,excluded,R,"For a white male patient with bladder urothelial carcinoma, a tumor mutation burden of 16.0, and transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the likelihood that he will respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, a tumor mutation burden of 16.0, and transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the likelihood that he will respond to Atezolizumab therapy? Please perform an in-depth gene expression analysis of the tumor microenvironment. Your analysis should include markers for exhausted and cytotoxic T cells, as well as markers for monocytes and macrophages. After obtaining the results, review current scientific literature to determine whether these biomarkers are consistently linked to the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1abf01-ar-1abf01d.pkl. "
BLCA,2.0,0.647058824,excluded,NR,"In a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of his tumor immune microenvironment from a kidney biopsy, and his TMB is 2.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of his tumor immune microenvironment from a kidney biopsy, and his TMB is 2.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Please conduct a comprehensive gene expression analysis of the tumor microenvironment. Focus on evaluating markers associated with exhausted and cytotoxic T cells, as well as indicators for monocytes and macrophages. After analyzing the data, review the latest scientific literature to assess whether these biomarkers are reproducibly linked to the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1ac4e3-ar-1ac4e3d.pkl. "
BLCA,,,excluded,NR,"I am evaluating a white female patient with bladder urothelial carcinoma. We have obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy; however, her tumor mutational burden (TMB) data is unavailable. Based on this information, is she likely to respond to Atezolizumab therapy?","I am evaluating a white female patient with bladder urothelial carcinoma. We have obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy; however, her tumor mutational burden (TMB) data is unavailable. Based on this information, is she likely to respond to Atezolizumab therapy? Please perform a detailed gene expression profiling of the tumor microenvironment. Focus specifically on markers that indicate exhausted and cytotoxic T cells, as well as those associated with monocytes and macrophages. Once your analysis is complete, review the most recent scientific literature to determine if these biomarkers consistently correlate with patients' responses to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1c0ecf-ar-1c0ecfb.pkl. "
BLCA,7.0,0.549019608,excluded,NR,"A white male patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutation burden of 7.0. Based on these findings, is it likely that the patient will respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutation burden of 7.0. Based on these findings, is it likely that the patient will respond to Atezolizumab therapy? Conduct a comprehensive gene expression analysis of the tumor microenvironment. Please focus on identifying markers for exhausted and cytotoxic T cells, as well as markers related to monocytes and macrophages. After completing your analysis, review the latest scientific literature to determine whether these biomarkers reliably correlate with patient treatment responses.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1c8b08-ar-1c8b086.pkl. "
BLCA,20.0,4.019607843,desert,NR,"I have a white male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment has been profiled transcriptomically from a bladder biopsy. With a tumor mutation burden (TMB) of 20, would you expect him to respond favorably to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment has been profiled transcriptomically from a bladder biopsy. With a tumor mutation burden (TMB) of 20, would you expect him to respond favorably to Atezolizumab therapy? Please perform a detailed gene expression profiling of the tumor microenvironment, concentrating on identifying markers for exhausted and cytotoxic T cells, along with those for monocytes and macrophages. After completing your analysis, review the most recent literature to assess whether these biomarkers consistently correlate with patient treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1dda30-ar-1dda30f.pkl. "
BLCA,5.0,1.431372549,inflamed,NR,"In a Caucasian female patient with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and transcriptomic data from her tumor immune microenvironment obtained via bladder biopsy, can we expect a response to Atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and transcriptomic data from her tumor immune microenvironment obtained via bladder biopsy, can we expect a response to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis of the tumor microenvironment. Focus on evaluating biomarkers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once completed, review the latest research to determine whether these markers are consistently associated with patient treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1e9c4d-ar-1e9c4d1.pkl. "
BLCA,38.0,4.509803922,inflamed,R,"I have a White male patient diagnosed with bladder urothelial carcinoma. His bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 38.0. Based on these findings, is there sufficient evidence to suggest that he would respond favorably to Atezolizumab therapy?","I have a White male patient diagnosed with bladder urothelial carcinoma. His bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 38.0. Based on these findings, is there sufficient evidence to suggest that he would respond favorably to Atezolizumab therapy? Please perform a comprehensive gene expression analysis of the tumor microenvironment, specifically focusing on biomarkers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review recent literature to determine whether these biomarkers are consistently linked with patient treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1f66db-ar-1f66db5.pkl. "
BLCA,6.0,0.549019608,desert,NR,"A white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment obtained from a kidney biopsy, and his tumor mutation burden is 6.0. Based on this information, what is the expected response to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment obtained from a kidney biopsy, and his tumor mutation burden is 6.0. Based on this information, what is the expected response to atezolizumab therapy? Please conduct a comprehensive gene expression profiling of the tumor microenvironment, concentrating on biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review current literature to assess whether these biomarkers are reliably associated with patient treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1f83eb-ar-1f83ebd.pkl. "
BLCA,8.0,1.235294118,inflamed,NR,"For a Caucasian patient with bladder urothelial carcinoma whose tumor immune microenvironment has been profiled via transcriptomics and a TMB of 8.0, based on these data are there indications that the patient might benefit from atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma whose tumor immune microenvironment has been profiled via transcriptomics and a TMB of 8.0, based on these data are there indications that the patient might benefit from atezolizumab therapy? Please perform an in-depth gene expression analysis of the tumor microenvironment, specifically targeting biomarkers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the results, review current scientific literature to evaluate whether these biomarkers have a consistent association with clinical treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1fa6bc-ar-1fa6bcb.pkl. "
BLCA,13.0,2.392156863,inflamed,R,"I have a white male patient with bladder urothelial carcinoma who underwent a bladder biopsy with transcriptomic profiling of the tumor immune microenvironment. With a tumor mutational burden of 13.0, is he likely to respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma who underwent a bladder biopsy with transcriptomic profiling of the tumor immune microenvironment. With a tumor mutational burden of 13.0, is he likely to respond to atezolizumab therapy? Perform a comprehensive gene expression analysis of the tumor microenvironment, focusing on biomarkers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the data is generated, examine current scientific literature to determine if these biomarkers consistently correlate with clinical treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/203dcf-ar-203dcf1.pkl. "
BLCA,5.0,0.294117647,excluded,NR,"In a white male patient with bladder urothelial carcinoma and a TMB of 5.0, can the transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy inform the likelihood of response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma and a TMB of 5.0, can the transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy inform the likelihood of response to Atezolizumab therapy? Conduct a detailed gene expression profiling of the tumor microenvironment, with an emphasis on biomarkers indicating exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the results, review the current scientific literature to assess whether these biomarkers consistently correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2070b4-ar-2070b41.pkl. "
BLCA,5.0,0.235294118,desert,NR,"In a Caucasian female patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reveals a tumor mutation burden of 5.0. Based on this data, should we expect a clinical response to Atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reveals a tumor mutation burden of 5.0. Based on this data, should we expect a clinical response to Atezolizumab therapy? Perform comprehensive gene expression analysis of the tumor microenvironment, focusing specifically on biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have the results, systematically review current scientific literature to determine if these biomarkers reliably correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/230959-ar-2309593.pkl. "
BLCA,5.0,0.333333333,excluded,NR,"For a white female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 5.0 and available transcriptomic data of the tumor immune microenvironment from a kidney biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 5.0 and available transcriptomic data of the tumor immune microenvironment from a kidney biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Conduct a thorough gene expression study of the tumor microenvironment, concentrating on biomarkers linked to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the data, review current scientific literature to assess whether these biomarkers consistently correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/23aa15-ar-23aa15d.pkl. "
BLCA,,1.823529412,desert,R,"Given a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile is available from a prior biopsy and with an unavailable tumor mutational burden (TMB) value, can we expect a favorable response to Atezolizumab therapy?","Given a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile is available from a prior biopsy and with an unavailable tumor mutational burden (TMB) value, can we expect a favorable response to Atezolizumab therapy? Perform a comprehensive gene expression analysis of the tumor microenvironment, with a specific focus on biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have collected the data, systematically review the current scientific literature to determine if these biomarkers consistently correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/25510f-ar-25510f3.pkl. "
BLCA,12.0,1.529411765,inflamed,R,"I have a Caucasian female patient with bladder urothelial carcinoma. Her tumor immune microenvironment, obtained via a lymph node biopsy, shows a transcriptomic profile with a tumor mutation burden of 12. Would she be likely to respond to Atezolizumab therapy?","I have a Caucasian female patient with bladder urothelial carcinoma. Her tumor immune microenvironment, obtained via a lymph node biopsy, shows a transcriptomic profile with a tumor mutation burden of 12. Would she be likely to respond to Atezolizumab therapy? Carry out a detailed analysis of gene expression in the tumor microenvironment, specifically assessing biomarkers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have obtained the data, review the existing scientific literature to evaluate whether these biomarkers are reliably associated with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2570ff-ar-2570ff4.pkl. "
BLCA,1.0,0.274509804,excluded,NR,"For an Asian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile reveals a tumor mutational burden of 1.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile reveals a tumor mutational burden of 1.0, what is the likelihood of a favorable response to Atezolizumab therapy? Perform an in-depth gene expression analysis of the tumor microenvironment with a focus on biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After collecting the data, review current scientific literature to determine whether these biomarkers are consistently linked to clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/26104d-ar-26104d5.pkl. "
BLCA,6.0,0.431372549,excluded,NR,"I have a white male patient with bladder urothelial carcinoma with a tumor mutational burden of 6.0. We obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. Based on this information, is there evidence to suggest that he would likely benefit from Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma with a tumor mutational burden of 6.0. We obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. Based on this information, is there evidence to suggest that he would likely benefit from Atezolizumab therapy? Conduct a comprehensive gene expression analysis of the tumor microenvironment with an emphasis on biomarkers relevant to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After data collection, review the latest scientific literature to evaluate how consistently these biomarkers correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/262422-ar-2624229.pkl. "
BLCA,8.0,0.745098039,excluded,R,"A 45-year-old female patient with bladder urothelial carcinoma (BLCA) has undergone a bladder biopsy, and we have obtained a transcriptomic profile of the tumor immune microenvironment. With a tumor mutational burden (TMB) of 8.0 mutations per megabase, what is the likelihood that she will respond favorably to Atezolizumab therapy?","A 45-year-old female patient with bladder urothelial carcinoma (BLCA) has undergone a bladder biopsy, and we have obtained a transcriptomic profile of the tumor immune microenvironment. With a tumor mutational burden (TMB) of 8.0 mutations per megabase, what is the likelihood that she will respond favorably to Atezolizumab therapy? Perform a detailed analysis of gene expression within the tumor microenvironment, focusing on biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have collected the data, review recent scientific literature to determine the consistency of these biomarkers in predicting clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/27299a-ar-27299ae.pkl. "
BLCA,6.0,0.568627451,inflamed,NR,"I have a white male patient with bladder urothelial carcinoma. His tumor mutational burden is 6.0, and we have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. Based on these data, what are the chances that he will respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. His tumor mutational burden is 6.0, and we have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. Based on these data, what are the chances that he will respond to Atezolizumab therapy? Conduct an in-depth evaluation of the gene expression profile within the tumor microenvironment, specifically targeting biomarkers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After data collection, review recent scientific literature to assess how consistently these biomarkers predict clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/286870-ar-2868703.pkl. "
BLCA,22.0,,desert,NR,"In my white male patient with bladder urothelial carcinoma and a tumor mutational burden of 22.0, based on the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, is Atezolizumab therapy likely to be effective?","In my white male patient with bladder urothelial carcinoma and a tumor mutational burden of 22.0, based on the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, is Atezolizumab therapy likely to be effective? Please perform a comprehensive analysis of the gene expression patterns in the tumor microenvironment, concentrating on biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once your data collection is complete, review recent literature to evaluate how reliably these biomarkers predict clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/28e603-ar-28e6031.pkl. "
BLCA,1.0,,excluded,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. The transcriptomic profile of his tumor immune microenvironment, obtained via bladder biopsy, shows a tumor mutational burden (TMB) of 1.0. Based on these findings, what is the likelihood of him responding to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. The transcriptomic profile of his tumor immune microenvironment, obtained via bladder biopsy, shows a tumor mutational burden (TMB) of 1.0. Based on these findings, what is the likelihood of him responding to Atezolizumab therapy? Please conduct a detailed analysis of gene expression patterns in the tumor microenvironment, specifically focusing on biomarkers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After gathering the necessary data, review recent studies to assess the reliability of these biomarkers in predicting clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/297c03-ar-297c030.pkl. "
BLCA,,0.490196078,desert,NR,"A white female patient with bladder urothelial carcinoma underwent a ureter biopsy to assess the tumor immune microenvironment. The transcriptomic profile is available, but the tumor mutation burden (TMB) could not be determined. Based on this information, is she likely to respond to Atezolizumab therapy?","A white female patient with bladder urothelial carcinoma underwent a ureter biopsy to assess the tumor immune microenvironment. The transcriptomic profile is available, but the tumor mutation burden (TMB) could not be determined. Based on this information, is she likely to respond to Atezolizumab therapy? Please perform a comprehensive assessment of gene expression within the tumor microenvironment, with an emphasis on biomarkers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After data collection, review current research to evaluate how reliably these biomarkers predict clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/29da92-ar-29da928.pkl. "
BLCA,2.0,0.156862745,desert,NR,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 2.0 and transcriptomic profiling data of the tumor immune microenvironment from a kidney biopsy, what is the anticipated response to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 2.0 and transcriptomic profiling data of the tumor immune microenvironment from a kidney biopsy, what is the anticipated response to atezolizumab therapy? Conduct a detailed analysis of gene expression in the tumor microenvironment, specifically focusing on biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After you have gathered the necessary data, review the latest research to determine how effectively these biomarkers predict clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2b672f-ar-2b672f4.pkl. "
BLCA,11.0,1.294117647,excluded,NR,"Given a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 11.0, could the transcriptomic profile of his tumor immune microenvironment from a bladder biopsy indicate a likely response to Atezolizumab therapy?","Given a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 11.0, could the transcriptomic profile of his tumor immune microenvironment from a bladder biopsy indicate a likely response to Atezolizumab therapy? Perform a comprehensive gene expression analysis within the tumor microenvironment, concentrating on biomarkers tied to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After collecting the relevant data, review recent literature to evaluate how well these biomarkers correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2bba8c-ar-2bba8cb.pkl. "
BLCA,9.0,0.431372549,desert,NR,"My White male patient with bladder urothelial carcinoma has a tumor mutational burden of 9.0 and available transcriptomic data from his tumor immune microenvironment biopsy. Based on this information, is Atezolizumab likely to be an effective therapeutic option?","My White male patient with bladder urothelial carcinoma has a tumor mutational burden of 9.0 and available transcriptomic data from his tumor immune microenvironment biopsy. Based on this information, is Atezolizumab likely to be an effective therapeutic option? Conduct a detailed gene expression study within the tumor microenvironment, focusing on markers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have collected the data, review recent research to determine how these biomarkers are associated with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2c9586-ar-2c95861.pkl. "
BLCA,,,inflamed,NR,"For a white male patient with bladder urothelial carcinoma, where we have a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy and an indeterminate tumor mutational burden, what considerations should be made regarding the likelihood of a response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, where we have a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy and an indeterminate tumor mutational burden, what considerations should be made regarding the likelihood of a response to atezolizumab therapy? Perform a comprehensive gene expression analysis in the tumor microenvironment, specifically targeting markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After collecting the data, review the latest scientific literature to identify and understand the relationship between these biomarkers and clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2dc3f0-ar-2dc3f04.pkl. "
BLCA,14.0,2.705882353,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA) who exhibits a tumor mutational burden of 14.0 and for whom we have a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, can we anticipate a favorable response to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA) who exhibits a tumor mutational burden of 14.0 and for whom we have a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, can we anticipate a favorable response to atezolizumab therapy? Conduct a detailed gene expression profiling study within the tumor microenvironment, focusing on markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the data are collected, review up-to-date scientific literature to analyze how these biomarkers correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2e7aa8-ar-2e7aa8f.pkl. "
BLCA,18.0,1.764705882,,R,"A white male patient diagnosed with bladder urothelial carcinoma (BLCA) has a tumor mutation burden of 18.0, and transcriptomic profiling of the tumor immune microenvironment has been performed on a bladder biopsy. Based on this data, is Atezolizumab therapy likely to be effective for this patient?","A white male patient diagnosed with bladder urothelial carcinoma (BLCA) has a tumor mutation burden of 18.0, and transcriptomic profiling of the tumor immune microenvironment has been performed on a bladder biopsy. Based on this data, is Atezolizumab therapy likely to be effective for this patient? Perform a comprehensive gene expression profiling study within the tumor microenvironment, specifically targeting markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After data collection, review current scientific literature to determine how these biomarkers correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2e9ac0-ar-2e9ac0b.pkl. "
BLCA,13.0,1.137254902,inflamed,R,"A white male patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutation burden (TMB) of 13.0. Based on these data, what is the likelihood that he will respond to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutation burden (TMB) of 13.0. Based on these data, what is the likelihood that he will respond to atezolizumab therapy? Conduct an in-depth gene expression analysis in the tumor microenvironment, focusing on markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once data collection is complete, systematically review the current scientific literature to assess how these biomarkers are linked to clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2eb07d-ar-2eb07de.pkl. "
BLCA,8.0,0.450980392,excluded,NR,"For an African American patient diagnosed with bladder urothelial carcinoma, our transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden of 8.0. Based on these findings, is there a likelihood of a positive response to atezolizumab therapy?","For an African American patient diagnosed with bladder urothelial carcinoma, our transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden of 8.0. Based on these findings, is there a likelihood of a positive response to atezolizumab therapy? Perform a comprehensive gene expression analysis within the tumor microenvironment, specifically targeting markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After gathering the data, review the current scientific literature systematically to determine how these biomarkers correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2f2289-ar-2f22893.pkl. "
BLCA,6.0,,excluded,R,"In a Caucasian female patient diagnosed with bladder urothelial carcinoma, with a tumor mutational burden of 6.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, is there evidence to suggest a response to Atezolizumab therapy?","In a Caucasian female patient diagnosed with bladder urothelial carcinoma, with a tumor mutational burden of 6.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, is there evidence to suggest a response to Atezolizumab therapy? Conduct a detailed gene expression analysis within the tumor microenvironment, focusing on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the data, systematically review the relevant scientific literature to assess the relationship between these biomarkers and clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/30b5c6-ar-30b5c6c.pkl. "
BLCA,,,excluded,NR,"In a white male patient with bladder urothelial carcinoma (BLCA), who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a missing TMB value, what is the likelihood that he will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA), who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a missing TMB value, what is the likelihood that he will respond to Atezolizumab therapy? Perform a comprehensive gene expression study in the tumor microenvironment, concentrating on markers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the data is collected, review the current scientific literature to determine how these biomarkers correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/30cf07-ar-30cf07d.pkl. "
BLCA,23.0,4.235294118,inflamed,R,"For a White male patient with bladder urothelial carcinoma and a tumor mutational burden of 23.0, where transcriptomic profiling of the tumor immune microenvironment has been performed on a bladder biopsy, would you anticipate a favorable response to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma and a tumor mutational burden of 23.0, where transcriptomic profiling of the tumor immune microenvironment has been performed on a bladder biopsy, would you anticipate a favorable response to Atezolizumab therapy? Conduct a detailed gene expression analysis of the tumor microenvironment, focusing on markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After gathering the data, review current scientific literature to assess the correlation between these biomarkers and clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/31d917-ar-31d9176.pkl. "
BLCA,,0.705882353,,NR,"For a white female patient with bladder urothelial carcinoma and available lymph node biopsy transcriptomic profiling of the tumor immune microenvironment, given that her reported tumor mutation burden is ""nan,"" what can we infer about her potential response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma and available lymph node biopsy transcriptomic profiling of the tumor immune microenvironment, given that her reported tumor mutation burden is ""nan,"" what can we infer about her potential response to Atezolizumab therapy? Perform a comprehensive gene expression profiling of the tumor microenvironment. This analysis should concentrate on biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the data are collected, review current scientific literature to evaluate how these biomarkers correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/31f41d-ar-31f41dd.pkl. "
BLCA,2.0,,,NR,"In a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 2.0, where the tumor immune microenvironment has been characterized by transcriptomic analysis of a lymph node biopsy, what is the likelihood that he will respond favorably to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 2.0, where the tumor immune microenvironment has been characterized by transcriptomic analysis of a lymph node biopsy, what is the likelihood that he will respond favorably to Atezolizumab therapy? Conduct an in-depth gene expression analysis of the tumor microenvironment, focusing on biomarkers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After gathering the data, review current scientific literature to assess the relationship between these biomarkers and patient clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3330c0-ar-3330c03.pkl. "
BLCA,,,,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma, and we obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. However, his tumor mutational burden data is not available. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma, and we obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. However, his tumor mutational burden data is not available. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Perform a thorough gene expression study of the tumor microenvironment, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have gathered your data, review recent scientific literature to understand how these biomarkers relate to patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/34430e-ar-34430ef.pkl. "
BLCA,7.0,0.333333333,excluded,NR,"I have a white male patient with bladder urothelial carcinoma. Based on his tumor immune microenvironment transcriptomic profile from a bladder biopsy and a tumor mutational burden of 7.0 mutations/Mb, can we predict a favorable response to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. Based on his tumor immune microenvironment transcriptomic profile from a bladder biopsy and a tumor mutational burden of 7.0 mutations/Mb, can we predict a favorable response to atezolizumab therapy? Conduct a detailed gene expression analysis of the tumor microenvironment, with a particular focus on markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After collecting the data, review current scientific literature to assess how these specific biomarkers correlate with patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36851b-ar-36851bc.pkl. "
BLCA,1.0,0.607843137,inflamed,NR,"For my Asian male patient diagnosed with bladder urothelial carcinoma, we have transcriptomic data from the tumor's immune microenvironment obtained via bladder biopsy and a tumor mutational burden of 1.0. Based on these findings, would you expect a favorable response to Atezolizumab therapy?","For my Asian male patient diagnosed with bladder urothelial carcinoma, we have transcriptomic data from the tumor's immune microenvironment obtained via bladder biopsy and a tumor mutational burden of 1.0. Based on these findings, would you expect a favorable response to Atezolizumab therapy? Perform a comprehensive gene expression analysis of the tumor microenvironment, emphasizing the evaluation of markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After gathering the data, review current scientific literature to determine how these biomarkers relate to patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36a922-ar-36a9225.pkl. "
BLCA,7.0,0.352941176,excluded,NR,"In a Caucasian male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment has been characterized via transcriptomic profiling of a ureter biopsy and who exhibits a tumor mutational burden (TMB) of 7.0, what is the likelihood of a favorable response to atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment has been characterized via transcriptomic profiling of a ureter biopsy and who exhibits a tumor mutational burden (TMB) of 7.0, what is the likelihood of a favorable response to atezolizumab therapy? Conduct a comprehensive gene expression analysis of the tumor microenvironment, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining and analyzing the data, review current scientific literature to assess how these biomarkers correlate with patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36d873-ar-36d8739.pkl. "
BLCA,5.0,,excluded,NR,"A Caucasian male patient with bladder urothelial carcinoma has a tumor mutational burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, is the patient likely to respond to atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a tumor mutational burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, is the patient likely to respond to atezolizumab therapy? Perform a detailed gene expression analysis of the tumor microenvironment, concentrating specifically on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have collected and analyzed the data, review current scientific literature to evaluate how these biomarkers are associated with patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3894ac-ar-3894ac3.pkl. "
BLCA,6.0,,excluded,NR,"I have a white male patient with bladder urothelial carcinoma. Transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden of 6.0. Based on these findings, what is the likelihood that he would respond favorably to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. Transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden of 6.0. Based on these findings, what is the likelihood that he would respond favorably to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis of the tumor microenvironment, with a focus on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the data analysis, review current scientific literature to evaluate the association between these biomarkers and patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/39eb94-ar-39eb94f.pkl. "
BLCA,,,,NR,"My white male patient with bladder urothelial carcinoma (BLCA) underwent a lung biopsy for transcriptomic profiling of the tumor immune microenvironment, and his tumor mutational burden (TMB) is reported as 'nan'. Given these findings, what are the implications for his potential response to Atezolizumab therapy?","My white male patient with bladder urothelial carcinoma (BLCA) underwent a lung biopsy for transcriptomic profiling of the tumor immune microenvironment, and his tumor mutational burden (TMB) is reported as 'nan'. Given these findings, what are the implications for his potential response to Atezolizumab therapy? Please perform a detailed gene expression analysis of the tumor microenvironment, specifically assessing markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Following this, review the current scientific literature to determine how these biomarkers relate to patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3a1c96-ar-3a1c963.pkl. "
BLCA,2.0,0.176470588,excluded,NR,"I have a Caucasian male patient with bladder urothelial carcinoma (BLCA), and transcriptomic profiling of his tumor immune microenvironment from a lymph node biopsy indicates a tumor mutational burden (TMB) of 2.0. Based on these findings, would you anticipate a favorable response to Atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma (BLCA), and transcriptomic profiling of his tumor immune microenvironment from a lymph node biopsy indicates a tumor mutational burden (TMB) of 2.0. Based on these findings, would you anticipate a favorable response to Atezolizumab therapy? Please conduct a comprehensive gene expression profiling of the tumor microenvironment, specifically analyzing markers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the latest scientific literature to evaluate how these biomarkers correlate with patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3b1066-ar-3b1066e.pkl. "
BLCA,44.0,5.823529412,inflamed,R,"For our Caucasian male patient with bladder urothelial carcinoma, whose tumor biopsy transcriptomic profiling reveals a tumor immune microenvironment with a TMB of 44.0, is there evidence to suggest he would likely benefit from Atezolizumab therapy?","For our Caucasian male patient with bladder urothelial carcinoma, whose tumor biopsy transcriptomic profiling reveals a tumor immune microenvironment with a TMB of 44.0, is there evidence to suggest he would likely benefit from Atezolizumab therapy? Please perform a detailed gene expression analysis of the tumor microenvironment with a focus on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have the profiling data, review current scientific literature to determine how these biomarkers may impact patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3b15b4-ar-3b15b4c.pkl. "
BLCA,15.0,2.235294118,excluded,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, the tumor immune microenvironment was profiled via transcriptomic analysis from a kidney biopsy, and the tumor mutational burden is 15.0. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, the tumor immune microenvironment was profiled via transcriptomic analysis from a kidney biopsy, and the tumor mutational burden is 15.0. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? Conduct a comprehensive gene expression analysis of the tumor microenvironment, with particular focus on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After you obtain the profiling data, review current scientific literature to evaluate the potential impact of these biomarkers on patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3cb94b-ar-3cb94b0.pkl. "
BLCA,17.0,1.411764706,excluded,R,"For a white male patient with bladder urothelial carcinoma, whose lymph node biopsy reveals the tumor immune microenvironment transcriptomic profile and a tumor mutation burden of 17.0, what is the likelihood that he will respond to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose lymph node biopsy reveals the tumor immune microenvironment transcriptomic profile and a tumor mutation burden of 17.0, what is the likelihood that he will respond to atezolizumab therapy? Perform a thorough gene expression analysis of the tumor microenvironment, with special emphasis on identifying markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have the profiling data, review the current scientific literature to assess how these biomarkers might influence patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3e04eb-ar-3e04eb9.pkl. "
BLCA,11.0,1.215686275,desert,NR,"In a case of a white male patient with bladder urothelial carcinoma, whose transcriptomic profile of the tumor immune microenvironment (obtained from a kidney biopsy) shows a tumor mutational burden of 11.0, can we expect a favorable response to atezolizumab therapy?","In a case of a white male patient with bladder urothelial carcinoma, whose transcriptomic profile of the tumor immune microenvironment (obtained from a kidney biopsy) shows a tumor mutational burden of 11.0, can we expect a favorable response to atezolizumab therapy? Conduct a comprehensive gene expression analysis of the tumor microenvironment, focusing on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the profiling data, consult up-to-date scientific literature to evaluate how these biomarkers may affect patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3e8baf-ar-3e8baff.pkl. "
BLCA,,,desert,NR,"In a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden is not quantifiable (TMB: nan). Based on these results, how can we predict or assess his likelihood of responding to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden is not quantifiable (TMB: nan). Based on these results, how can we predict or assess his likelihood of responding to Atezolizumab therapy? Perform a comprehensive gene expression analysis of the tumor microenvironment, specifically targeting markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have the profiling data, review current scientific literature to assess the potential impact of these biomarkers on patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3ee5dc-ar-3ee5dcd.pkl. "
BLCA,,0.431372549,excluded,NR,"I have a white male patient with bladder urothelial carcinoma, and we recently obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Since the tumor mutational burden (TMB) is not available, can these data help predict whether the patient will respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma, and we recently obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Since the tumor mutational burden (TMB) is not available, can these data help predict whether the patient will respond to Atezolizumab therapy? Conduct a thorough gene expression analysis of the tumor microenvironment, focusing specifically on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining this profiling data, review recent scientific literature to determine how these biomarkers may influence patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/415f36-ar-415f36a.pkl. "
BLCA,12.0,0.392156863,desert,NR,"For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile (from a bladder biopsy) indicates a tumor mutational burden of 12.0, based on these findings, is there an expectation of response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile (from a bladder biopsy) indicates a tumor mutational burden of 12.0, based on these findings, is there an expectation of response to atezolizumab therapy? Perform a comprehensive gene expression analysis of the tumor microenvironment by specifically assessing markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have compiled the profiling data, review the current scientific literature to evaluate the potential impact of these biomarkers on patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4305ab-ar-4305ab9.pkl. "
BLCA,6.0,0.921568627,excluded,NR,"In my white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 6.0, how should the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy guide my decision regarding the use of Atezolizumab therapy?","In my white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 6.0, how should the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy guide my decision regarding the use of Atezolizumab therapy? Conduct a detailed analysis of gene expression within the tumor microenvironment, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After gathering the profiling data, review the current literature to assess how these biomarkers might influence patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4501e4-ar-4501e41.pkl. "
BLCA,5.0,1.392156863,inflamed,NR,"For a Caucasian patient with bladder urothelial carcinoma (BLCA), where transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy is available and the tumor mutation burden (TMB) is 5.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma (BLCA), where transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy is available and the tumor mutation burden (TMB) is 5.0, what is the likelihood of a favorable response to Atezolizumab therapy? Perform a comprehensive analysis of gene expression in tumor samples, with a specific focus on identifying markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Following data collection, conduct a thorough review of current literature to determine how these biomarkers may correlate with patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/45c8e6-ar-45c8e64.pkl. "
BLCA,8.0,,desert,NR,"In a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 8.0 and a transcriptomic profile of the tumor immune microenvironment obtained via nanobiopsy, what is the likelihood of a clinical response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 8.0 and a transcriptomic profile of the tumor immune microenvironment obtained via nanobiopsy, what is the likelihood of a clinical response to Atezolizumab therapy? Please perform a detailed gene expression analysis on tumor samples, concentrating on markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After collecting the data, review the current literature thoroughly to assess how these biomarkers might be associated with patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/468a9e-ar-468a9e1.pkl. "
BLCA,8.0,0.803921569,inflamed,NR,"A Caucasian patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 8.0. Based on these findings, can we expect a favorable response to Atezolizumab therapy?","A Caucasian patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 8.0. Based on these findings, can we expect a favorable response to Atezolizumab therapy? Conduct a comprehensive gene expression analysis of tumor samples, focusing specifically on markers that indicate the presence of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the data has been collected, perform a thorough review of the current literature to evaluate the potential links between these biomarkers and patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/47fc46-ar-47fc46c.pkl. "
BLCA,0.0,0.607843137,excluded,NR,"A patient with bladder urothelial carcinoma has a transcriptomic profile of their tumor immune microenvironment from a bladder biopsy and a tumor mutation burden of 0.0. Based on this data, how likely is the patient to respond to Atezolizumab therapy?","A patient with bladder urothelial carcinoma has a transcriptomic profile of their tumor immune microenvironment from a bladder biopsy and a tumor mutation burden of 0.0. Based on this data, how likely is the patient to respond to Atezolizumab therapy? Perform a detailed gene expression analysis on tumor samples to identify markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After gathering the data, review current literature to assess how these biomarkers relate to patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/49d487-ar-49d4875.pkl. "
BLCA,5.0,1.450980392,excluded,NR,A Caucasian male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment from a kidney biopsy and a tumor mutational burden (TMB) of 5.0. What is the likelihood that he will respond to Atezolizumab therapy?,"A Caucasian male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment from a kidney biopsy and a tumor mutational burden (TMB) of 5.0. What is the likelihood that he will respond to Atezolizumab therapy? Conduct a comprehensive gene expression analysis on tumor samples to detect markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the data is collected, systematically review recent literature to determine how these biomarkers correlate with patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/49f9b2-ar-49f9b2e.pkl. "
BLCA,6.0,,desert,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, is there evidence to suggest that he would respond favorably to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, is there evidence to suggest that he would respond favorably to Atezolizumab therapy? Please perform a detailed gene expression analysis on tumor tissue, specifically targeting markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After gathering the data, review the current research literature to evaluate how these immune biomarkers relate to patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4b0175-ar-4b0175e.pkl. "
BLCA,,,excluded,NR,"I have a white female patient with bladder urothelial carcinoma. Based on a transcriptomic analysis of her tumor immune microenvironment obtained from a kidney biopsy and an indeterminate tumor mutational burden, is there evidence to suggest that she will respond favorably to atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma. Based on a transcriptomic analysis of her tumor immune microenvironment obtained from a kidney biopsy and an indeterminate tumor mutational burden, is there evidence to suggest that she will respond favorably to atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor tissue, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the data is collected, review the current literature to assess the relationship between these immune biomarkers and patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4b7ea0-ar-4b7ea01.pkl. "
BLCA,59.0,11.68627451,excluded,R,"My patient is a White male diagnosed with bladder urothelial carcinoma (BLCA). We have obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, and his tumor mutation burden (TMB) is 59.0. Based on these findings, how likely is it that he will respond to atezolizumab therapy?","My patient is a White male diagnosed with bladder urothelial carcinoma (BLCA). We have obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, and his tumor mutation burden (TMB) is 59.0. Based on these findings, how likely is it that he will respond to atezolizumab therapy? Please conduct a detailed gene expression analysis on the tumor sample, concentrating on markers that indicate the presence of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After gathering the data, review current scientific literature to evaluate how these specific immune biomarkers correlate with patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4caabd-ar-4caabd6.pkl. "
BLCA,13.0,0.31372549,desert,NR,"A white male patient with bladder urothelial carcinoma (BLCA) has a tumor transcriptomic profile from a kidney biopsy characterizing the immune microenvironment, and his tumor mutational burden (TMB) is 13.0. Based on these findings, can we expect a favorable response to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma (BLCA) has a tumor transcriptomic profile from a kidney biopsy characterizing the immune microenvironment, and his tumor mutational burden (TMB) is 13.0. Based on these findings, can we expect a favorable response to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor sample, specifically targeting markers that identify exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the data is collected, review the latest scientific literature to assess how these immune biomarkers are linked to patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/523468-ar-5234688.pkl. "
BLCA,12.0,0.745098039,excluded,NR,"Given a patient with bladder urothelial carcinoma who has a tumor mutation burden of 12.0 and a transcriptomic profile of the tumor immune microenvironment from a ureteral biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","Given a patient with bladder urothelial carcinoma who has a tumor mutation burden of 12.0 and a transcriptomic profile of the tumor immune microenvironment from a ureteral biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Conduct a detailed gene expression profiling of the tumor sample, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After data collection, review the current scientific literature to determine the association between these immune biomarkers and patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/52500c-ar-52500ca.pkl. "
BLCA,4.0,0.254901961,,NR,"Considering a white male patient with bladder urothelial carcinoma who has a transcriptomic profile from a lymph node biopsy and a tumor mutational burden of 4.0, what is the likelihood that this patient will respond to Atezolizumab therapy?","Considering a white male patient with bladder urothelial carcinoma who has a transcriptomic profile from a lymph node biopsy and a tumor mutational burden of 4.0, what is the likelihood that this patient will respond to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor sample, specifically targeting markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the data, review recent scientific literature to evaluate how these immune biomarkers correlate with patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/52e3fa-ar-52e3fa3.pkl. "
BLCA,11.0,1.823529412,desert,R,"In a Caucasian male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Considering a tumor mutational burden of 11.0, what is the likelihood that this patient will respond to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Considering a tumor mutational burden of 11.0, what is the likelihood that this patient will respond to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis of the tumor sample, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Afterward, review the latest scientific literature to assess how these immune biomarkers may be linked to patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/548551-ar-548551e.pkl. "
BLCA,5.0,,desert,NR,"For a Caucasian male patient with bladder urothelial carcinoma and a tumor mutational burden of 5.0, based on the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the anticipated likelihood of response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma and a tumor mutational burden of 5.0, based on the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the anticipated likelihood of response to Atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor sample, concentrating on identifying markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Following the analysis, review current scientific literature to evaluate the potential relationships between these immune biomarkers and patient outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/54e58f-ar-54e58f1.pkl. "
BLCA,,,,NR,"My Caucasian female patient has been diagnosed with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and her tumor mutation burden (TMB) is reported as ""nan."" Based on these findings, is she likely to respond to atezolizumab therapy?","My Caucasian female patient has been diagnosed with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and her tumor mutation burden (TMB) is reported as ""nan."" Based on these findings, is she likely to respond to atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor sample, with a focus on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review recent scientific literature to determine how these immune biomarkers might correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/553c3c-ar-553c3c3.pkl. "
BLCA,5.0,,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile was obtained via ureter biopsy and with a tumor mutational burden of 5.0, is there evidence to suggest a favorable response to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile was obtained via ureter biopsy and with a tumor mutational burden of 5.0, is there evidence to suggest a favorable response to atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor sample, specifically examining markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review current scientific literature to assess how these immune markers correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/557dde-ar-557dde1.pkl. "
BLCA,19.0,0.647058824,inflamed,R,"My native Hawaiian or other Pacific Islander male patient with bladder urothelial carcinoma has a tumor mutational burden of 19.0, and we have a transcriptomic profile of his tumor immune microenvironment from a prior biopsy. Based on these findings, is he likely to respond to atezolizumab therapy?","My native Hawaiian or other Pacific Islander male patient with bladder urothelial carcinoma has a tumor mutational burden of 19.0, and we have a transcriptomic profile of his tumor immune microenvironment from a prior biopsy. Based on these findings, is he likely to respond to atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor sample, focusing on markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the latest scientific literature to determine how these immune markers may correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/560f23-ar-560f23d.pkl. "
BLCA,,0.607843137,,NR,"We have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy is available, although his tumor mutation burden (TMB) was not determined (reported as NaN). Based on these results, what is the likelihood that he will respond to Atezolizumab therapy?","We have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy is available, although his tumor mutation burden (TMB) was not determined (reported as NaN). Based on these results, what is the likelihood that he will respond to Atezolizumab therapy? Please conduct an in-depth gene expression analysis of the tumor sample, specifically evaluating markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is completed, review recent scientific literature to assess how these immune markers may be linked to clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/563d62-ar-563d623.pkl. "
BLCA,,,,NR,"In a Caucasian female patient with bladder urothelial carcinoma, we obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, but her tumor mutation burden is unavailable. Based on these data, what is the likelihood of her responding to atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma, we obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, but her tumor mutation burden is unavailable. Based on these data, what is the likelihood of her responding to atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor tissue, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review recent scientific literature to determine how these immune markers may correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/568ce1-ar-568ce16.pkl. "
BLCA,33.0,5.509803922,excluded,R,"We have a white male patient with bladder urothelial carcinoma, for whom we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. With a tumor mutation burden of 33.0, can we anticipate a favorable response to Atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma, for whom we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. With a tumor mutation burden of 33.0, can we anticipate a favorable response to Atezolizumab therapy? Please conduct a thorough gene expression profiling of the tumor tissue, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the most recent scientific literature to assess how these immune markers correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/572f19-ar-572f197.pkl. "
BLCA,32.0,,excluded,R,"I have a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 32. Additionally, we obtained a transcriptomic profile of the tumor immune microenvironment from a previous biopsy. Based on these results, would you expect the patient to respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 32. Additionally, we obtained a transcriptomic profile of the tumor immune microenvironment from a previous biopsy. Based on these results, would you expect the patient to respond to Atezolizumab therapy? Please perform comprehensive gene expression profiling on the tumor tissue, specifically evaluating markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review the latest scientific literature to determine how these immune markers are associated with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5767dd-ar-5767dd7.pkl. "
BLCA,2.0,0.333333333,desert,R,"I have a Caucasian male patient with bladder urothelial carcinoma. Based on the transcriptomic profile of the tumor immune microenvironment from the bladder biopsy and a tumor mutation burden of 2.0, can we expect a favorable response to atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma. Based on the transcriptomic profile of the tumor immune microenvironment from the bladder biopsy and a tumor mutation burden of 2.0, can we expect a favorable response to atezolizumab therapy? Please conduct a detailed gene expression analysis on the tumor specimen, specifically targeting markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have completed the analysis, review current scientific literature to determine the relationship between these immune markers and clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/58e783-ar-58e7832.pkl. "
BLCA,14.0,,excluded,NR,"In a patient with bladder urothelial carcinoma, with a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy and a tumor mutational burden of 14.0, how likely is it that the patient will respond to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma, with a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy and a tumor mutational burden of 14.0, how likely is it that the patient will respond to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor specimen, focusing on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review recent scientific literature to assess how these immune markers correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/59f392-ar-59f3928.pkl. "
BLCA,,,,NR,"In a Caucasian male patient with bladder urothelial carcinoma, how should we interpret the transcriptomic profile obtained from a nanobiopsy of the tumor immune microenvironment, in conjunction with a TMB value of nan, in predicting the likelihood of response to atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, how should we interpret the transcriptomic profile obtained from a nanobiopsy of the tumor immune microenvironment, in conjunction with a TMB value of nan, in predicting the likelihood of response to atezolizumab therapy? Please conduct a detailed gene expression profiling of the tumor specimen, concentrating on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Following the analysis, review current scientific literature to evaluate how these immune markers relate to clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/59fda9-ar-59fda90.pkl. "
BLCA,9.0,1.333333333,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 9.0 and available transcriptomic data from the tumor immune microenvironment obtained via bladder biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 9.0 and available transcriptomic data from the tumor immune microenvironment obtained via bladder biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Please perform comprehensive gene expression profiling on the tumor specimen, specifically targeting markers of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have completed the analysis, review the relevant scientific literature to assess how these immune markers correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5a2347-ar-5a2347c.pkl. "
BLCA,12.0,,,NR,"For an Asian female patient with bladder urothelial carcinoma and a tumor mutation burden (TMB) of 12.0, assessed via transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy, is there evidence to suggest a favorable response to Atezolizumab therapy?","For an Asian female patient with bladder urothelial carcinoma and a tumor mutation burden (TMB) of 12.0, assessed via transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy, is there evidence to suggest a favorable response to Atezolizumab therapy? Perform a comprehensive gene expression analysis on the tumor sample, specifically assessing markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the current scientific literature to evaluate how these immune markers correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5b57e4-ar-5b57e47.pkl. "
BLCA,,,excluded,NR,"My white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, but his TMB value is not available. Based on this information, can we predict his likelihood of responding to Atezolizumab therapy?","My white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, but his TMB value is not available. Based on this information, can we predict his likelihood of responding to Atezolizumab therapy? Conduct a comprehensive gene expression profiling of the tumor specimen, with particular focus on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the profiling is completed, review current scientific literature to determine how these immune markers relate to clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5c139c-ar-5c139c5.pkl. "
BLCA,11.0,0.411764706,desert,NR,"A white male patient with bladder urothelial carcinoma has a tumor transcriptomic profile from a bladder biopsy and a tumor mutation burden of 11.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a tumor transcriptomic profile from a bladder biopsy and a tumor mutation burden of 11.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Please perform an extensive gene expression analysis on the tumor sample, with special attention to immune markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Following the analysis, review the latest scientific literature to evaluate how these immune markers are associated with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5cc2d9-ar-5cc2d90.pkl. "
BLCA,10.0,1.215686275,,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) who exhibits a tumor mutation burden of 10.0 and has had transcriptomic profiling of the tumor immune microenvironment from a liver biopsy, what is the anticipated response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who exhibits a tumor mutation burden of 10.0 and has had transcriptomic profiling of the tumor immune microenvironment from a liver biopsy, what is the anticipated response to Atezolizumab therapy? Conduct a comprehensive gene expression profiling of the tumor tissue, concentrating on immune markers for exhausted and cytotoxic T cells as well as monocytes and macrophages. Once the analysis is complete, review recent research to determine how these markers correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5cfa16-ar-5cfa169.pkl. "
BLCA,12.0,,,NR,"I have a Caucasian male patient with bladder urothelial carcinoma who exhibits a tumor mutation burden (TMB) of 12.0 mutations/Mb and a tumor immune microenvironment characterized by a transcriptomic profile from a bladder biopsy. Based on these findings, what insights can we draw regarding his potential response to atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma who exhibits a tumor mutation burden (TMB) of 12.0 mutations/Mb and a tumor immune microenvironment characterized by a transcriptomic profile from a bladder biopsy. Based on these findings, what insights can we draw regarding his potential response to atezolizumab therapy? Perform a detailed gene expression analysis on the tumor tissue, focusing primarily on immune markers that indicate exhausted and cytotoxic T cells, as well as monocytes and macrophages. After obtaining the results, review current research to assess how these markers relate to clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5d1dfd-ar-5d1dfd5.pkl. "
BLCA,13.0,1.411764706,desert,NR,"Given a female patient with bladder urothelial carcinoma, a tumor mutational burden of 13.0, and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, do we have evidence that she is likely to respond to Atezolizumab therapy?","Given a female patient with bladder urothelial carcinoma, a tumor mutational burden of 13.0, and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, do we have evidence that she is likely to respond to Atezolizumab therapy? Conduct an in-depth gene expression analysis on the tumor sample, emphasizing immune markers linked to exhausted and cytotoxic T cells as well as monocytes and macrophages. After obtaining the data, review the latest research to evaluate how these markers correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5d989c-ar-5d989c8.pkl. "
BLCA,6.0,0.823529412,excluded,NR,"I am managing a Caucasian male patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed by transcriptomic profiling from a kidney biopsy. Given his tumor mutation burden of 6.0 mutations per megabase, what is the likelihood that he will respond favorably to Atezolizumab therapy?","I am managing a Caucasian male patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed by transcriptomic profiling from a kidney biopsy. Given his tumor mutation burden of 6.0 mutations per megabase, what is the likelihood that he will respond favorably to Atezolizumab therapy? Perform a comprehensive gene expression analysis on the tumor sample, focusing specifically on immune markers for exhausted and cytotoxic T cells as well as markers for monocytes and macrophages. Once the analysis is complete, review contemporary research to determine how these markers are associated with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5e3bae-ar-5e3bae0.pkl. "
BLCA,21.0,3.823529412,inflamed,NR,"We have a white male patient with bladder urothelial carcinoma whose ureter biopsy transcriptomic profiling of the tumor immune microenvironment revealed a tumor mutational burden of 21.0. Based on these results, how likely is he to respond to Atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma whose ureter biopsy transcriptomic profiling of the tumor immune microenvironment revealed a tumor mutational burden of 21.0. Based on these results, how likely is he to respond to Atezolizumab therapy? Please conduct a detailed gene expression analysis of the tumor sample, specifically assessing markers for exhausted and cytotoxic T cells along with markers for monocytes and macrophages. After completing the analysis, review the latest scientific literature to evaluate how these markers correlate with clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5fe7a8-ar-5fe7a81.pkl. "
BLCA,14.0,,inflamed,R,"I have a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0. Given the transcriptomic profile of his tumor immune microenvironment obtained from a bladder biopsy, what is the likelihood that he will respond to atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0. Given the transcriptomic profile of his tumor immune microenvironment obtained from a bladder biopsy, what is the likelihood that he will respond to atezolizumab therapy? Please perform a thorough gene expression analysis on the tumor sample. Focus on evaluating markers associated with both exhausted and cytotoxic T cells, as well as markers for monocytes and macrophages. Once the analysis is complete, review recent scientific literature to determine how these markers relate to clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6083aa-ar-6083aac.pkl. "
BLCA,9.0,1.803921569,desert,R,"A white male patient with bladder urothelial carcinoma has a tumor biopsy with a transcriptomic profile of the immune microenvironment and a tumor mutational burden of 9.0. Based on these findings, can we expect a response to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a tumor biopsy with a transcriptomic profile of the immune microenvironment and a tumor mutational burden of 9.0. Based on these findings, can we expect a response to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor sample, specifically assessing markers for exhausted and cytotoxic T cells, as well as monocytes and macrophages. After the analysis, review current scientific literature to understand the clinical significance of these markers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6157c8-ar-6157c8f.pkl. "
BLCA,27.0,5.882352941,inflamed,NR,"In a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 27.0, can the transcriptomic profile of his tumor immune microenvironment inform the likelihood of a favorable response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 27.0, can the transcriptomic profile of his tumor immune microenvironment inform the likelihood of a favorable response to atezolizumab therapy? Please perform a thorough gene expression analysis on the tumor sample to evaluate markers for exhausted and cytotoxic T cells, as well as for monocytes and macrophages. Once this analysis is complete, review the current scientific literature to determine the clinical implications of these markers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/61b9d4-ar-61b9d4d.pkl. "
BLCA,,,desert,NR,"I am managing a White female patient with bladder urothelial carcinoma. We obtained a transcriptomic profile from a lymph node biopsy of her tumor immune microenvironment, but her tumor mutation burden (TMB) is not available. Based on these findings, what are the implications for her potential response to atezolizumab therapy?","I am managing a White female patient with bladder urothelial carcinoma. We obtained a transcriptomic profile from a lymph node biopsy of her tumor immune microenvironment, but her tumor mutation burden (TMB) is not available. Based on these findings, what are the implications for her potential response to atezolizumab therapy? Please conduct a comprehensive gene expression analysis of the tumor specimen, focusing on markers associated with both exhausted and cytotoxic T cells, as well as monocytes and macrophages. After completing this analysis, review the latest scientific literature to assess the clinical relevance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/61baf9-ar-61baf91.pkl. "
BLCA,5.0,0.784313725,,NR,"For a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained via kidney biopsy, is there evidence to suggest that she would respond favorably to Atezolizumab therapy?","For a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained via kidney biopsy, is there evidence to suggest that she would respond favorably to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor specimen, ensuring you specifically assess markers for exhausted and cytotoxic T cells, as well as for monocytes and macrophages. Once the analysis is complete, review the most recent scientific literature to determine the clinical significance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/62fb13-ar-62fb138.pkl. "
BLCA,,0.156862745,,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden is not available. Based on these findings, can we reasonably anticipate a response to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden is not available. Based on these findings, can we reasonably anticipate a response to Atezolizumab therapy? Please conduct a thorough gene expression profiling on the tumor sample, with a particular emphasis on markers for both exhausted and cytotoxic T cells, as well as for monocytes and macrophages. After completing the analysis, review current scientific literature to assess the clinical relevance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/63405b-ar-63405b0.pkl. "
BLCA,14.0,0.980392157,desert,NR,"I am managing a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 14.0. We have also obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","I am managing a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 14.0. We have also obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor tissue, specifically focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review the latest scientific literature to determine the clinical significance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/63b218-ar-63b2189.pkl. "
BLCA,4.0,0.294117647,excluded,NR,"In a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis of the immune microenvironment indicates a tumor mutation burden of 4.0, how likely is it that he will respond to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis of the immune microenvironment indicates a tumor mutation burden of 4.0, how likely is it that he will respond to atezolizumab therapy? Please conduct a comprehensive gene expression profiling of the tumor tissue, focusing on identifying markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the most recent scientific literature to evaluate the clinical relevance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/65afda-ar-65afda2.pkl. "
BLCA,5.0,0.490196078,inflamed,NR,"For a white male patient with bladder urothelial carcinoma and a TMB of 5.0, based on the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, how likely is it that he will respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma and a TMB of 5.0, based on the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, how likely is it that he will respond to Atezolizumab therapy? Please perform an in-depth gene expression analysis on the tumor tissue to detect markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the profiling is complete, review the latest relevant scientific literature to determine the clinical implications of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6662f5-ar-6662f51.pkl. "
BLCA,15.0,2.68627451,excluded,R,"In a Caucasian female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 15.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, is there evidence to suggest that she would respond favorably to Atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 15.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, is there evidence to suggest that she would respond favorably to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor tissue, focusing on markers specific for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the most recent scientific literature to clarify the clinical significance of these identified biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/670649-ar-670649e.pkl. "
BLCA,13.0,1.254901961,desert,NR,"For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 13.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that he will respond favorably to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 13.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that he will respond favorably to atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor tissue, specifically examining markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review current peer-reviewed research to determine the clinical relevance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/675a12-ar-675a12a.pkl. "
BLCA,14.0,2.549019608,inflamed,NR,"In a Caucasian female patient with bladder urothelial carcinoma and a tumor mutation burden of 14.0, based on the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, is there an indication that she will respond favorably to atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma and a tumor mutation burden of 14.0, based on the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, is there an indication that she will respond favorably to atezolizumab therapy? Please conduct a comprehensive gene expression profiling of the tumor tissue, with a specific focus on markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review contemporary peer-reviewed literature to assess the clinical significance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6780ed-ar-6780ed4.pkl. "
BLCA,17.0,1.117647059,desert,NR,"For a Black or African American male patient with bladder urothelial carcinoma, documented with a tumor mutation burden of 17.0 and transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","For a Black or African American male patient with bladder urothelial carcinoma, documented with a tumor mutation burden of 17.0 and transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, based on these findings, what is the likelihood of a favorable response to atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor tissue, focusing specifically on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review recent peer-reviewed literature to understand the clinical significance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6792d6-ar-6792d6e.pkl. "
BLCA,7.0,1.862745098,excluded,R,"We have a white male patient with bladder urothelial carcinoma (BLCA), a tumor mutational burden of 7.0, and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma (BLCA), a tumor mutational burden of 7.0, and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? Please conduct a thorough gene expression analysis on the tumor tissue, specifically focusing on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the latest peer-reviewed studies to assess the clinical implications of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/681e4b-ar-681e4bf.pkl. "
BLCA,5.0,1.176470588,,NR,"In our White male patient with bladder urothelial carcinoma and a tumor mutational burden (TMB) of 5.0, the transcriptomic profile of the tumor immune microenvironment from his bladder biopsy is available. Based on these findings, is Atezolizumab likely to be an effective treatment option for him?","In our White male patient with bladder urothelial carcinoma and a tumor mutational burden (TMB) of 5.0, the transcriptomic profile of the tumor immune microenvironment from his bladder biopsy is available. Based on these findings, is Atezolizumab likely to be an effective treatment option for him? Perform a comprehensive gene expression profiling of the tumor tissue, focusing specifically on markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review the most recent peer-reviewed literature to evaluate the clinical implications of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6964a6-ar-6964a6d.pkl. "
BLCA,20.0,1.039215686,desert,R,"I am managing a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 20.0. We have also obtained transcriptomic data from a lung biopsy of his tumor immune microenvironment. Based on these parameters, what is the likelihood that he will respond to Atezolizumab therapy?","I am managing a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 20.0. We have also obtained transcriptomic data from a lung biopsy of his tumor immune microenvironment. Based on these parameters, what is the likelihood that he will respond to Atezolizumab therapy? Please conduct a detailed gene expression analysis on the tumor tissue, specifically examining markers that indicate the presence of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the latest peer-reviewed research to understand the clinical relevance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6cb230-ar-6cb230f.pkl. "
BLCA,3.0,0.960784314,inflamed,NR,"For a white male patient with bladder urothelial carcinoma, the tumor transcriptomic profile from a bladder biopsy shows a TMB of 3.0. Based on this molecular data, is he likely to benefit from Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, the tumor transcriptomic profile from a bladder biopsy shows a TMB of 3.0. Based on this molecular data, is he likely to benefit from Atezolizumab therapy? Conduct a comprehensive gene expression analysis on the tumor sample, concentrating on markers that identify exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review the most current peer-reviewed literature to evaluate the clinical significance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6cbc10-ar-6cbc10a.pkl. "
BLCA,,,excluded,NR,"My Black/African American male patient has bladder urothelial carcinoma. We obtained a transcriptomic profile of his tumor immune microenvironment from a lymph node biopsy, and the tumor mutation burden (TMB) is not available. Given this information, is Atezolizumab therapy likely to be effective for him?","My Black/African American male patient has bladder urothelial carcinoma. We obtained a transcriptomic profile of his tumor immune microenvironment from a lymph node biopsy, and the tumor mutation burden (TMB) is not available. Given this information, is Atezolizumab therapy likely to be effective for him? Perform a detailed gene expression analysis on the tumor sample, specifically targeting markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the latest peer-reviewed literature to determine the clinical relevance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6d2ae0-ar-6d2ae0c.pkl. "
BLCA,,3.568627451,,NR,"For a white male patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, but his tumor mutational burden is not available. Based on these data, can we predict if he will respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, but his tumor mutational burden is not available. Based on these data, can we predict if he will respond to Atezolizumab therapy? Please perform a thorough gene expression profiling on the tumor sample, focusing on markers that identify exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once completed, review the most recent peer-reviewed literature to assess the clinical significance of these identified biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6dd7ad-ar-6dd7ad1.pkl. "
BLCA,8.0,2.078431373,,R,"In a white female patient with bladder urothelial carcinoma (BLCA), where the tumor's immune microenvironment transcriptomic profile was obtained via nanobiopsy and the tumor mutation burden (TMB) is 8.0, how likely is she to respond to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma (BLCA), where the tumor's immune microenvironment transcriptomic profile was obtained via nanobiopsy and the tumor mutation burden (TMB) is 8.0, how likely is she to respond to Atezolizumab therapy? Please conduct comprehensive gene expression profiling on the tumor sample, specifically analyzing markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the profiling is complete, review the latest peer-reviewed literature to evaluate the clinical relevance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6f2a10-ar-6f2a102.pkl. "
BLCA,6.0,1.039215686,excluded,R,"I have a white male patient with bladder urothelial carcinoma. Transcriptomic profiling of his tumor immune microenvironment, obtained from a kidney biopsy, indicates a tumor mutation burden of 6.0. Based on these findings, can we predict a favorable response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. Transcriptomic profiling of his tumor immune microenvironment, obtained from a kidney biopsy, indicates a tumor mutation burden of 6.0. Based on these findings, can we predict a favorable response to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor specimen, ensuring that you include markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the most recent peer-reviewed studies to assess the clinical significance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6ff654-ar-6ff654a.pkl. "
BLCA,17.0,2.176470588,,NR,"In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 17.0 and available transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy, could these findings predict a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 17.0 and available transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy, could these findings predict a favorable response to Atezolizumab therapy? Perform a detailed gene expression profiling of the tumor specimen, including markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review recent peer-reviewed studies to determine the clinical relevance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7114d9-ar-7114d99.pkl. "
BLCA,6.0,1.568627451,,NR,"In a Caucasian male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden of 6.0 and for whom we have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, is there evidence to suggest that he would respond favorably to atezolizumab therapy?","In a Caucasian male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden of 6.0 and for whom we have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, is there evidence to suggest that he would respond favorably to atezolizumab therapy? Please perform comprehensive gene expression analysis on the tumor sample, including assessment of markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review recent peer-reviewed literature to determine the clinical significance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/716f54-ar-716f54e.pkl. "
BLCA,1.0,0.333333333,,R,"I have a Caucasian male patient with bladder urothelial carcinoma (BLCA) whose lymph node biopsy provided a transcriptomic profile of the tumor immune microenvironment. Given that his tumor mutational burden is 1.0, can we expect him to respond to Atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma (BLCA) whose lymph node biopsy provided a transcriptomic profile of the tumor immune microenvironment. Given that his tumor mutational burden is 1.0, can we expect him to respond to Atezolizumab therapy? Please perform a comprehensive gene expression profiling on the tumor sample, ensuring you evaluate biomarkers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review the latest peer-reviewed studies to interpret the clinical relevance of these findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/727c0e-ar-727c0e9.pkl. "
BLCA,,,excluded,R,"I have a Caucasian male patient with bladder urothelial carcinoma. We performed a kidney biopsy to analyze the transcriptomic profile of the tumor immune microenvironment, but the tumor mutational burden data is not available. Based on this information, can we predict whether he is likely to respond to atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma. We performed a kidney biopsy to analyze the transcriptomic profile of the tumor immune microenvironment, but the tumor mutational burden data is not available. Based on this information, can we predict whether he is likely to respond to atezolizumab therapy? Kindly conduct an extensive gene expression analysis on the tumor specimen, with specific attention to biomarkers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Upon completion of the analysis, please review the latest peer-reviewed literature to evaluate the clinical relevance of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/73663e-ar-73663ee.pkl. "
BLCA,7.0,0.274509804,excluded,NR,"I have a White female patient diagnosed with bladder urothelial carcinoma with a tumor mutation burden of 7.0. A transcriptomic analysis of her tumor immune microenvironment was performed using a kidney biopsy sample. Based on these findings, should we expect a favorable response to Atezolizumab therapy?","I have a White female patient diagnosed with bladder urothelial carcinoma with a tumor mutation burden of 7.0. A transcriptomic analysis of her tumor immune microenvironment was performed using a kidney biopsy sample. Based on these findings, should we expect a favorable response to Atezolizumab therapy? Please perform a comprehensive gene expression profiling on the tumor sample, focusing on biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the most recent peer-reviewed literature to determine the clinical significance of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/75142f-ar-75142fc.pkl. "
BLCA,21.0,2.392156863,inflamed,NR,"In a Caucasian female patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 21, what is the likelihood of a favorable response to atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 21, what is the likelihood of a favorable response to atezolizumab therapy? Conduct a thorough gene expression analysis of the tumor sample, with a specific focus on biomarkers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review the latest findings published in peer-reviewed journals to evaluate the clinical relevance of the detected markers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7538ad-ar-7538ad9.pkl. "
BLCA,7.0,,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma and a tumor mutational burden of 7.0, how might the transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy inform the expected response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma and a tumor mutational burden of 7.0, how might the transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy inform the expected response to Atezolizumab therapy? Please perform a detailed gene expression analysis of the tumor specimen, specifically targeting biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review recent peer-reviewed literature to determine the clinical significance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/753d4b-ar-753d4bb.pkl. "
BLCA,6.0,0.333333333,inflamed,NR,"I have a White male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 6.0. We obtained a transcriptomic profile of his tumor immune microenvironment from a lung biopsy. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","I have a White male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 6.0. We obtained a transcriptomic profile of his tumor immune microenvironment from a lung biopsy. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor specimen with a focus on identifying biomarkers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review the latest peer-reviewed studies to assess the clinical relevance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/75f12d-ar-75f12d1.pkl. "
BLCA,6.0,0.215686275,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 6.0 and transcriptomic profiling of the tumor immune microenvironment obtained from a kidney biopsy, is there evidence to suggest that this patient is likely to respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 6.0 and transcriptomic profiling of the tumor immune microenvironment obtained from a kidney biopsy, is there evidence to suggest that this patient is likely to respond to Atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor specimen, specifically targeting markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review current peer-reviewed literature to determine the clinical significance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/76a431-ar-76a431b.pkl. "
BLCA,,0.215686275,inflamed,R,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma, we have a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, but his tumor mutational burden is not available. Based on this information, can we predict whether he is likely to respond to Atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma, we have a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, but his tumor mutational burden is not available. Based on this information, can we predict whether he is likely to respond to Atezolizumab therapy? Conduct a comprehensive gene expression study on the tumor tissue, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the latest peer-reviewed research to evaluate the clinical relevance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/771445-ar-771445e.pkl. "
BLCA,3.0,0.745098039,inflamed,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled via transcriptomics from a bladder biopsy. With a tumor mutational burden of 3.0, is he likely to respond to atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled via transcriptomics from a bladder biopsy. With a tumor mutational burden of 3.0, is he likely to respond to atezolizumab therapy? Perform a comprehensive gene expression analysis on the tumor tissue, specifically examining markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review current, high-quality peer-reviewed literature to assess the clinical significance of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7829a3-ar-7829a34.pkl. "
BLCA,5.0,0.941176471,,NR,"In an Asian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0 and a characterized transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, how likely is it that he will respond to Atezolizumab therapy?","In an Asian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0 and a characterized transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, how likely is it that he will respond to Atezolizumab therapy? Conduct an in-depth gene expression analysis on the tumor tissue, focusing on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review current, high-quality peer-reviewed studies to evaluate the clinical implications of these biomarkers.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/789319-ar-7893196.pkl. "
BLCA,,1.039215686,excluded,NR,"For my white male patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, but his tumor mutational burden is not available. Based on this information, can we predict whether he will respond to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, but his tumor mutational burden is not available. Based on this information, can we predict whether he will respond to Atezolizumab therapy? Perform a detailed gene expression analysis on the tumor tissue, concentrating on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, compare the findings against current, high-quality peer-reviewed literature to determine their clinical significance.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7aa01f-ar-7aa01fc.pkl. "
BLCA,12.0,,,R,"For a Caucasian female patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic analysis from a ureter biopsy indicates a tumor mutational burden of 12.0, is Atezolizumab therapy likely to be effective?","For a Caucasian female patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic analysis from a ureter biopsy indicates a tumor mutational burden of 12.0, is Atezolizumab therapy likely to be effective? Conduct a comprehensive gene expression analysis on the tumor tissue, specifically focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, systematically compare your results with the latest high-quality, peer-reviewed research to assess their clinical relevance.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7b4000-ar-7b40007.pkl. "
BLCA,,0.725490196,,NR,"For a Caucasian patient with bladder urothelial carcinoma, we have obtained transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy, and the tumor mutational burden (TMB) is reported as not available (nan). Based on this information, can we predict the likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma, we have obtained transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy, and the tumor mutational burden (TMB) is reported as not available (nan). Based on this information, can we predict the likelihood of a favorable response to Atezolizumab therapy? Perform a detailed gene expression analysis on the tumor tissue, concentrating on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review and compare your findings with the most recent, high-quality peer-reviewed studies to determine their clinical relevance.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7bff23-ar-7bff231.pkl. "
BLCA,5.0,0.529411765,,NR,"In a white female patient with bladder urothelial carcinoma, where the tumor immune microenvironment has been profiled transcriptomically from a bladder biopsy and the tumor mutational burden is 5.0, what is the likelihood of a therapeutic response to atezolizumab?","In a white female patient with bladder urothelial carcinoma, where the tumor immune microenvironment has been profiled transcriptomically from a bladder biopsy and the tumor mutational burden is 5.0, what is the likelihood of a therapeutic response to atezolizumab? Conduct a comprehensive gene expression analysis on the tumor tissue, targeting markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, compare your results with the most current, high-quality peer-reviewed studies to evaluate their clinical relevance.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7c67b0-ar-7c67b05.pkl. "
BLCA,4.0,0.156862745,inflamed,NR,"For a White male patient with bladder urothelial carcinoma, whose lymph node biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 4.0, what is the likelihood that he will respond to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma, whose lymph node biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 4.0, what is the likelihood that he will respond to Atezolizumab therapy? Please perform an in-depth gene expression profiling of the tumor specimen with a focus on identifying markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, critically compare your findings with the latest high-quality, peer-reviewed studies to determine their clinical significance.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7d2dfb-ar-7d2dfba.pkl. "
BLCA,8.0,2.098039216,excluded,R,"I have a white male patient diagnosed with bladder urothelial carcinoma. His bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutational burden of 8.0. Based on these findings, is it likely that the patient will respond favorably to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. His bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutational burden of 8.0. Based on these findings, is it likely that the patient will respond favorably to Atezolizumab therapy? Conduct a thorough gene expression analysis of the tumor specimen, paying particular attention to markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the results, please compare them in detail with recent high-quality, peer-reviewed studies to evaluate their clinical relevance.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7d7c54-ar-7d7c546.pkl. "
BLCA,,,excluded,NR,"My Caucasian male patient with bladder urothelial carcinoma has a transcriptomic profile available from a biopsy of the tumor immune microenvironment. Given that the tumor mutational burden data is not available, can we reliably predict his response to Atezolizumab therapy?","My Caucasian male patient with bladder urothelial carcinoma has a transcriptomic profile available from a biopsy of the tumor immune microenvironment. Given that the tumor mutational burden data is not available, can we reliably predict his response to Atezolizumab therapy? Please perform a comprehensive gene expression profiling on the tumor specimen, ensuring you specifically assess markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you obtain the results, compare them in detail with contemporary, high-quality peer-reviewed studies to determine their clinical significance.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7f0d9c-ar-7f0d9cc.pkl. "
BLCA,1.0,,excluded,NR,"I have a Black/African American male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment has been characterized through transcriptomic analysis from a bladder biopsy. Given his tumor mutational burden (TMB) of 1.0, is there evidence to suggest that he would benefit from Atezolizumab therapy?","I have a Black/African American male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment has been characterized through transcriptomic analysis from a bladder biopsy. Given his tumor mutational burden (TMB) of 1.0, is there evidence to suggest that he would benefit from Atezolizumab therapy? Please conduct a thorough gene expression analysis on the tumor tissue, with a focus on identifying markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the results, carefully compare them with current, high-quality peer-reviewed studies to evaluate their clinical relevance.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7fb698-ar-7fb6987.pkl. "
BLCA,11.0,0.764705882,excluded,NR,"In an Asian male patient with bladder urothelial carcinoma and a tumor mutation burden of 11, with transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, would you expect a response to Atezolizumab therapy?","In an Asian male patient with bladder urothelial carcinoma and a tumor mutation burden of 11, with transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, would you expect a response to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor tissue, focusing on detecting markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have the results, review them in the context of the latest high-quality peer-reviewed studies to assess their clinical significance.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7fb7a1-ar-7fb7a13.pkl. "
BLCA,8.0,0.215686275,inflamed,NR,"For our white male patient with bladder urothelial carcinoma, whose kidney biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutation burden (TMB) of 8.0, what response can we expect from Atezolizumab therapy?","For our white male patient with bladder urothelial carcinoma, whose kidney biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutation burden (TMB) of 8.0, what response can we expect from Atezolizumab therapy? Please conduct a thorough gene expression analysis on the tumor tissue, specifically looking for markers that indicate the presence of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review the findings by comparing them with the latest high-quality, peer-reviewed research to determine their clinical relevance.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/80c618-ar-80c6183.pkl. "
BLCA,7.0,1.078431373,,NR,"Does this white female patient with bladder urothelial carcinoma, who has a tumor mutation burden of 7.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, have a profile that predicts a likely response to atezolizumab therapy?","Does this white female patient with bladder urothelial carcinoma, who has a tumor mutation burden of 7.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, have a profile that predicts a likely response to atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor tissue, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, compare the results with the latest high-quality, peer-reviewed literature to assess their clinical significance.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/81b715-ar-81b7152.pkl. "
BLCA,,1.098039216,desert,NR,"Given a white male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of his tumor immune microenvironment from a previous biopsy, and with tumor mutation burden (TMB) not determined, how likely is it that he will respond to Atezolizumab therapy?","Given a white male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of his tumor immune microenvironment from a previous biopsy, and with tumor mutation burden (TMB) not determined, how likely is it that he will respond to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor tissue, with a specific focus on identifying markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, carefully compare your findings with the most recent, high-quality peer-reviewed literature to evaluate their potential clinical implications.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/822b22-ar-822b226.pkl. "
BLCA,5.0,1.725490196,desert,R,"For a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 5.0, can the transcriptomic profile of the tumor immune microenvironment from the bladder biopsy help predict a response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 5.0, can the transcriptomic profile of the tumor immune microenvironment from the bladder biopsy help predict a response to Atezolizumab therapy? Please perform a detailed gene expression profiling of the tumor tissue, focusing on identifying markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you complete the analysis, compare the results with up-to-date, high-quality peer-reviewed literature to determine their potential clinical significance.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8533e5-ar-8533e5e.pkl. "
BLCA,8.0,0.274509804,excluded,NR,"I have a Caucasian male patient with bladder urothelial carcinoma (BLCA) for whom we obtained a transcriptomic profile of the tumor immune microenvironment from a lung biopsy. The tumor mutation burden is 8.0. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma (BLCA) for whom we obtained a transcriptomic profile of the tumor immune microenvironment from a lung biopsy. The tumor mutation burden is 8.0. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy? Conduct a comprehensive gene expression analysis on the tumor tissue, with an emphasis on detecting markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review current, high-quality peer-reviewed literature to assess the clinical relevance of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/85f0a3-ar-85f0a3a.pkl. "
BLCA,14.0,0.31372549,excluded,NR,"A white female patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile from a bladder biopsy and a tumor mutational burden (TMB) of 14. Given these findings, what is the likelihood that she will respond to Atezolizumab therapy?","A white female patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile from a bladder biopsy and a tumor mutational burden (TMB) of 14. Given these findings, what is the likelihood that she will respond to Atezolizumab therapy? Perform a detailed gene expression analysis of the tumor tissue, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review current, high-quality peer-reviewed literature to evaluate the clinical significance of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/87a8e1-ar-87a8e18.pkl. "
BLCA,13.0,6.0,inflamed,R,"In a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment has been profiled transcriptomically from a bladder biopsy and who has a tumor mutation burden of 13.0, what is the expected clinical response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment has been profiled transcriptomically from a bladder biopsy and who has a tumor mutation burden of 13.0, what is the expected clinical response to atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor tissue, specifically targeting markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the results, review recent high-quality, peer-reviewed studies to determine the clinical implications of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8884fe-ar-8884fe4.pkl. "
BLCA,14.0,0.843137255,desert,R,"For an Asian male patient with bladder urothelial carcinoma (BLCA), whose tumor biopsy reveals a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden (TMB) of 14, is there evidence to suggest a favorable response to Atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma (BLCA), whose tumor biopsy reveals a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden (TMB) of 14, is there evidence to suggest a favorable response to Atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor tissue, focusing on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have the results, review recent, high-quality peer-reviewed literature to assess the clinical relevance of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8a1b0e-ar-8a1b0e0.pkl. "
BLCA,7.0,1.0,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma who has a TMB of 7.0 and for whom we have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, what is the likelihood of a response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma who has a TMB of 7.0 and for whom we have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, what is the likelihood of a response to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor sample, specifically evaluating markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Following your analysis, review current high-quality, peer-reviewed literature to determine the clinical relevance of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8b4b8b-ar-8b4b8b0.pkl. "
BLCA,6.0,,excluded,NR,"I am evaluating a Caucasian male patient with bladder urothelial carcinoma. The tumor sample from his bladder biopsy has been profiled for its immune microenvironment transcriptomics and shows a tumor mutational burden (TMB) of 6.0. Given these findings, is a response to Atezolizumab therapy likely?","I am evaluating a Caucasian male patient with bladder urothelial carcinoma. The tumor sample from his bladder biopsy has been profiled for its immune microenvironment transcriptomics and shows a tumor mutational burden (TMB) of 6.0. Given these findings, is a response to Atezolizumab therapy likely? Please perform a detailed gene expression analysis on the tumor sample, with a particular focus on identifying markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the latest high-quality, peer-reviewed studies to assess the clinical significance of your results.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8e4698-ar-8e46983.pkl. "
BLCA,6.0,0.509803922,desert,NR,"I have a Caucasian male patient with bladder urothelial carcinoma whose tumor immune microenvironment was transcriptomically profiled from a kidney biopsy. Given his tumor mutational burden of 6.0, do you anticipate that he would likely respond to Atezolizumab treatment?","I have a Caucasian male patient with bladder urothelial carcinoma whose tumor immune microenvironment was transcriptomically profiled from a kidney biopsy. Given his tumor mutational burden of 6.0, do you anticipate that he would likely respond to Atezolizumab treatment? Please conduct a comprehensive gene expression profiling of the tumor sample, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have completed the analysis, review the latest peer-reviewed studies to evaluate the clinical relevance of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8e8ef2-ar-8e8ef23.pkl. "
BLCA,5.0,,desert,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 5.0. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 5.0. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor sample, specifically examining markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, cross-reference your findings with the latest peer-reviewed literature to determine their clinical significance.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8f2275-ar-8f2275c.pkl. "
BLCA,49.0,2.705882353,inflamed,R,"For our Caucasian male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden (TMB) is 49.0. Based on these findings, would you anticipate a favorable response to Atezolizumab therapy?","For our Caucasian male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden (TMB) is 49.0. Based on these findings, would you anticipate a favorable response to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor sample, paying particular attention to markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review the most recent peer-reviewed literature to assess the clinical relevance of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/91c47b-ar-91c47b0.pkl. "
BLCA,12.0,2.235294118,inflamed,NR,"Our Caucasian male patient with bladder urothelial carcinoma has a tumor mutation burden of 12.0. Based on the transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy, what is the likelihood of his response to Atezolizumab therapy?","Our Caucasian male patient with bladder urothelial carcinoma has a tumor mutation burden of 12.0. Based on the transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy, what is the likelihood of his response to Atezolizumab therapy? Please perform a detailed gene expression profiling on the tumor sample. Focus specifically on markers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the latest peer-reviewed research to determine the clinical significance of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9306c5-ar-9306c5c.pkl. "
BLCA,,,,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) who has a transcriptomic profile of the tumor immune microenvironment from a biopsy and unavailable tumor mutational burden data, what is the likelihood of a favorable response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has a transcriptomic profile of the tumor immune microenvironment from a biopsy and unavailable tumor mutational burden data, what is the likelihood of a favorable response to atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor sample, paying particular attention to markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once your analysis is complete, consult the latest peer-reviewed literature to evaluate the clinical implications of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9410b8-ar-9410b86.pkl. "
BLCA,5.0,0.117647059,desert,NR,"I am treating a Caucasian male patient diagnosed with bladder urothelial carcinoma. We have obtained the transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 5.0. Based on these findings, can we expect a favorable response to atezolizumab therapy?","I am treating a Caucasian male patient diagnosed with bladder urothelial carcinoma. We have obtained the transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 5.0. Based on these findings, can we expect a favorable response to atezolizumab therapy? Please perform a detailed gene expression profiling on the tumor sample, focusing on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the most recent peer-reviewed studies to interpret the clinical relevance of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/943df5-ar-943df5c.pkl. "
BLCA,11.0,0.215686275,excluded,NR,"My Black or African American patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden (TMB) of 11.0, and I have a transcriptomic profile from a kidney biopsy detailing the tumor immune microenvironment. Given these data, is it likely that the patient will respond to atezolizumab therapy?","My Black or African American patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden (TMB) of 11.0, and I have a transcriptomic profile from a kidney biopsy detailing the tumor immune microenvironment. Given these data, is it likely that the patient will respond to atezolizumab therapy? Please conduct a thorough gene expression analysis on the tumor sample, specifically examining markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review the latest peer-reviewed literature to help interpret the clinical significance of the results.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/94859b-ar-94859b4.pkl. "
BLCA,,0.431372549,desert,NR,"We have a white male patient diagnosed with bladder urothelial carcinoma who underwent a bladder biopsy with transcriptomic profiling of the tumor immune microenvironment. The tumor mutation burden (TMB) is reported as ""nan."" Based on these findings, what is the likelihood that the patient will respond to atezolizumab therapy?","We have a white male patient diagnosed with bladder urothelial carcinoma who underwent a bladder biopsy with transcriptomic profiling of the tumor immune microenvironment. The tumor mutation burden (TMB) is reported as ""nan."" Based on these findings, what is the likelihood that the patient will respond to atezolizumab therapy? Please perform a detailed gene expression evaluation on the tumor specimen, specifically targeting markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the most recent peer-reviewed literature to contextualize and interpret the clinical importance of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9539a4-ar-9539a4f.pkl. "
BLCA,,0.196078431,excluded,NR,"In a white male patient with bladder urothelial carcinoma who underwent a ureter biopsy for transcriptomic profiling of his tumor immune microenvironment, the tumor mutational burden (TMB) is not available. Based on the current molecular data, what is the likelihood that he will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma who underwent a ureter biopsy for transcriptomic profiling of his tumor immune microenvironment, the tumor mutational burden (TMB) is not available. Based on the current molecular data, what is the likelihood that he will respond to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor sample, specifically examining markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review the latest peer-reviewed research to help interpret the clinical significance of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/957378-ar-957378b.pkl. "
BLCA,17.0,1.725490196,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 17.0, what is the anticipated likelihood of response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 17.0, what is the anticipated likelihood of response to Atezolizumab therapy? Please conduct a thorough gene expression analysis on the tumor sample, focusing on markers that identify exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the latest peer-reviewed studies to help determine the clinical implications of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/961d04-ar-961d04c.pkl. "
BLCA,22.0,4.431372549,desert,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA). The tumor biopsy shows a transcriptomic profile of the immune microenvironment and a tumor mutation burden (TMB) of 22.0. Based on these findings, would you expect the patient to respond favorably to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA). The tumor biopsy shows a transcriptomic profile of the immune microenvironment and a tumor mutation burden (TMB) of 22.0. Based on these findings, would you expect the patient to respond favorably to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor sample, specifically examining markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review the most recent peer-reviewed literature to assess the clinical significance of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/972530-ar-9725303.pkl. "
BLCA,,1.921568627,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA), given that the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy is available and the tumor mutational burden (TMB) is reported as unavailable (nan), is there evidence to suggest that the patient would respond favorably to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA), given that the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy is available and the tumor mutational burden (TMB) is reported as unavailable (nan), is there evidence to suggest that the patient would respond favorably to Atezolizumab therapy? Please conduct a detailed gene expression analysis on the tumor sample, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing this analysis, review the latest peer-reviewed studies to determine the clinical relevance of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/978a58-ar-978a587.pkl. "
BLCA,18.0,2.862745098,excluded,R,"For a patient with bladder urothelial carcinoma who has a tumor mutation burden of 18 and transcriptomic profiling data of the tumor immune microenvironment (obtained via kidney biopsy), what is the likelihood of a favorable response to Atezolizumab therapy?","For a patient with bladder urothelial carcinoma who has a tumor mutation burden of 18 and transcriptomic profiling data of the tumor immune microenvironment (obtained via kidney biopsy), what is the likelihood of a favorable response to Atezolizumab therapy? Please perform an in-depth gene expression analysis of the tumor sample, concentrating on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review the most recent peer-reviewed studies to assess the clinical implications of the findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/97a00e-ar-97a00e0.pkl. "
BLCA,5.0,0.725490196,excluded,NR,"For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what are the prospects for a clinical response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what are the prospects for a clinical response to atezolizumab therapy? Conduct a comprehensive gene expression analysis on the tumor sample, specifically targeting markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is completed, review the latest peer-reviewed literature to interpret the clinical significance of the findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/99a46b-ar-99a46b9.pkl. "
BLCA,4.0,0.862745098,inflamed,NR,"In my Caucasian male patient with bladder urothelial carcinoma, the tumor mutation burden is 4.0 and I have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","In my Caucasian male patient with bladder urothelial carcinoma, the tumor mutation burden is 4.0 and I have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor sample, focusing on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review recent peer-reviewed studies to help interpret the clinical relevance of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9a2cf3-ar-9a2cf3c.pkl. "
BLCA,5.0,0.647058824,excluded,NR,"I have a white male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and his tumor mutational burden is 5.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and his tumor mutational burden is 5.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Conduct a comprehensive gene expression analysis on the tumor sample, emphasizing markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review the latest peer-reviewed literature to contextualize the clinical significance of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9aa6a0-ar-9aa6a09.pkl. "
BLCA,12.0,0.588235294,inflamed,NR,"I have a White male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomics were obtained via kidney biopsy. Given his TMB of 12.0, is he likely to respond to Atezolizumab therapy?","I have a White male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomics were obtained via kidney biopsy. Given his TMB of 12.0, is he likely to respond to Atezolizumab therapy? Perform a detailed gene expression analysis of the tumor sample, specifically targeting markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review current peer-reviewed research to accurately interpret and contextualize the clinical implications of your results.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9cafb9-ar-9cafb90.pkl. "
BLCA,,,,NR,"For this white male patient with bladder urothelial carcinoma, who has a transcriptomic profile of the tumor immune microenvironment from a liver biopsy and an unavailable TMB, what is the likelihood of a response to Atezolizumab therapy?","For this white male patient with bladder urothelial carcinoma, who has a transcriptomic profile of the tumor immune microenvironment from a liver biopsy and an unavailable TMB, what is the likelihood of a response to Atezolizumab therapy? Conduct a comprehensive gene expression analysis on the tumor sample, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the results, review the latest peer-reviewed literature to accurately interpret and contextualize the clinical significance of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9d2494-ar-9d24941.pkl. "
BLCA,,,desert,NR,"For a Caucasian female patient with bladder urothelial carcinoma (BLCA), based on the transcriptomic profile of her tumor immune microenvironment obtained from a kidney biopsy and an undetermined tumor mutational burden, is Atezolizumab therapy likely to be effective?","For a Caucasian female patient with bladder urothelial carcinoma (BLCA), based on the transcriptomic profile of her tumor immune microenvironment obtained from a kidney biopsy and an undetermined tumor mutational burden, is Atezolizumab therapy likely to be effective? Perform a detailed gene expression analysis of the tumor sample, specifically targeting markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have the results, review the most recent peer-reviewed literature to properly interpret and integrate these findings into their clinical context.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9dacca-ar-9daccaf.pkl. "
BLCA,10.0,,inflamed,NR,"A white male patient with bladder urothelial carcinoma has a tumor mutational burden of 10.0, and we have transcriptomic data from his bladder biopsy detailing the tumor immune microenvironment. Based on these findings, is he likely to respond to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a tumor mutational burden of 10.0, and we have transcriptomic data from his bladder biopsy detailing the tumor immune microenvironment. Based on these findings, is he likely to respond to atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor sample, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After acquiring the results, review the latest peer-reviewed literature to assist in interpreting these findings within the appropriate clinical context.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9e11ec-ar-9e11ec6.pkl. "
BLCA,6.0,0.431372549,desert,NR,"For a white female patient with bladder urothelial carcinoma (BLCA) whose tumor biopsy transcriptomic profile of the immune microenvironment shows a tumor mutational burden (TMB) of 6.0, what is the likelihood of a response to atezolizumab therapy based on these findings?","For a white female patient with bladder urothelial carcinoma (BLCA) whose tumor biopsy transcriptomic profile of the immune microenvironment shows a tumor mutational burden (TMB) of 6.0, what is the likelihood of a response to atezolizumab therapy based on these findings? Please perform a detailed gene expression analysis on the tumor specimen, specifically targeting markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the data is collected, review the most current peer-reviewed literature to help interpret these findings within the appropriate clinical context.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9fb814-ar-9fb814c.pkl. "
BLCA,,3.333333333,desert,NR,"For a white female patient diagnosed with bladder urothelial carcinoma, we have a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, but the tumor mutation burden is not available (NaN). Based on these data, can we predict whether she will respond to atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma, we have a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, but the tumor mutation burden is not available (NaN). Based on these data, can we predict whether she will respond to atezolizumab therapy? Please conduct an in-depth gene expression analysis of the tumor specimen, focusing on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have collected the data, review the most recent peer-reviewed literature to appropriately interpret these findings in a clinical context.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a1871f-ar-a1871f4.pkl. "
BLCA,15.0,0.921568627,inflamed,NR,"In a Caucasian female patient with bladder urothelial carcinoma who has a tumor mutation burden of 15.0 and transcriptomic data from a bladder biopsy characterizing the tumor immune microenvironment, what is the likelihood of response to Atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma who has a tumor mutation burden of 15.0 and transcriptomic data from a bladder biopsy characterizing the tumor immune microenvironment, what is the likelihood of response to Atezolizumab therapy? Please perform a comprehensive gene expression analysis of the tumor sample, emphasizing markers that indicate the presence of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the data, review current peer-reviewed research to guide the clinical interpretation of these findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a1e62d-ar-a1e62d3.pkl. "
BLCA,8.0,1.411764706,excluded,NR,"In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 8.0 and a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 8.0 and a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Please conduct an in-depth gene expression analysis of the tumor specimen, specifically examining markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have the results, review the latest peer-reviewed literature to inform your clinical interpretation of these findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a32177-ar-a321770.pkl. "
BLCA,6.0,0.68627451,,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) who has a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy and a tumor mutation burden (TMB) of 6.0, is the tumor likely to respond to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy and a tumor mutation burden (TMB) of 6.0, is the tumor likely to respond to atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor tissue, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the results, consult the most recent peer-reviewed studies to guide your clinical interpretation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a424c7-ar-a424c75.pkl. "
BLCA,19.0,0.882352941,,R,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 19.0. We obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. Based on these results, is he likely to respond favorably to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 19.0. We obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. Based on these results, is he likely to respond favorably to Atezolizumab therapy? Perform a detailed gene expression profiling of the tumor tissue, specifically evaluating markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have the results, please review the latest peer-reviewed literature to inform your clinical interpretation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a535fc-ar-a535fcd.pkl. "
BLCA,12.0,0.725490196,,NR,"For a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a prior biopsy is available and the tumor mutational burden is 12.0. Based on this information, what evidence is there regarding the likelihood of response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a prior biopsy is available and the tumor mutational burden is 12.0. Based on this information, what evidence is there regarding the likelihood of response to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis of the tumor tissue with a focus on biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the results, review the most recent peer-reviewed literature to guide your clinical interpretation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a90d73-ar-a90d73f.pkl. "
BLCA,,1.529411765,excluded,NR,"My white male patient has bladder urothelial carcinoma. I have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutation burden is not available. Can we predict whether he will respond to Atezolizumab therapy?","My white male patient has bladder urothelial carcinoma. I have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutation burden is not available. Can we predict whether he will respond to Atezolizumab therapy? Please perform a thorough gene expression analysis on the tumor tissue, concentrating on biomarkers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have the results, review the latest peer-reviewed literature to inform your clinical interpretation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a913c6-ar-a913c61.pkl. "
BLCA,3.0,0.352941176,,NR,"In a white male patient with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden of 3.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a clinical response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden of 3.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a clinical response to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor tissue with a focus on identifying biomarkers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the analysis results, review current, peer-reviewed literature to support your clinical interpretation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a9ca85-ar-a9ca853.pkl. "
BLCA,18.0,2.0,,NR,"In a Caucasian male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy. With a tumor mutational burden of 18.0, what is the likelihood that the patient will respond to atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy. With a tumor mutational burden of 18.0, what is the likelihood that the patient will respond to atezolizumab therapy? Perform a detailed gene expression analysis on the tumor tissue to identify biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review current, peer-reviewed literature to provide context and support for your clinical interpretation of the results.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aabf4a-ar-aabf4af.pkl. "
BLCA,15.0,1.725490196,excluded,R,"In a white male patient with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy reveals a tumor mutation burden of 15.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy reveals a tumor mutation burden of 15.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis of the tumor tissue to identify biomarkers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the latest peer-reviewed literature to support and contextualize your clinical interpretation of the findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aaf505-ar-aaf505c.pkl. "
BLCA,,0.039215686,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment through a lymph node biopsy, but the tumor mutation burden (TMB) data is not available (nan). Given these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment through a lymph node biopsy, but the tumor mutation burden (TMB) data is not available (nan). Given these findings, what is the likelihood that the patient will respond to Atezolizumab therapy? Please perform an extensive gene expression analysis on the tumor tissue to detect biomarkers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review and reference current peer-reviewed research to inform your clinical interpretation of the findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ab8052-ar-ab8052a.pkl. "
BLCA,,,excluded,NR,"In my Caucasian female patient with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile from her bladder biopsy shows a tumor mutation burden (TMB) reported as ""nan."" Based on these findings, what is the likelihood that she will respond to Atezolizumab therapy?","In my Caucasian female patient with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile from her bladder biopsy shows a tumor mutation burden (TMB) reported as ""nan."" Based on these findings, what is the likelihood that she will respond to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor tissue to identify biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review current peer-reviewed research to support your clinical interpretation of the results.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/abc151-ar-abc151b.pkl. "
BLCA,6.0,0.745098039,,NR,"I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy reveals a tumor mutation burden of 6.0. Based on these findings, what is the likelihood that the patient will benefit from Atezolizumab treatment?","I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy reveals a tumor mutation burden of 6.0. Based on these findings, what is the likelihood that the patient will benefit from Atezolizumab treatment? Please perform a full gene expression analysis on the tumor sample to identify biomarkers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the results, review recent peer‐reviewed literature to guide your clinical interpretation of these findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ad83c9-ar-ad83c9c.pkl. "
BLCA,,,,NR,"For a white female patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of her tumor immune microenvironment from a kidney biopsy, but her tumor mutational burden data is unavailable. Based on this information, how might we predict her responsiveness to atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of her tumor immune microenvironment from a kidney biopsy, but her tumor mutational burden data is unavailable. Based on this information, how might we predict her responsiveness to atezolizumab therapy? Please conduct a comprehensive gene expression profiling of the tumor sample to identify biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have obtained the analysis results, review the latest peer‐reviewed literature to inform your clinical interpretation of the findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae0262-ar-ae02629.pkl. "
BLCA,,,,NR,"I have a Black or African American male patient with bladder urothelial carcinoma who underwent a ureter biopsy for transcriptomic analysis of the tumor immune microenvironment. Given that the tumor mutation burden is not available, could you provide guidance on whether this patient is likely to respond to atezolizumab therapy?","I have a Black or African American male patient with bladder urothelial carcinoma who underwent a ureter biopsy for transcriptomic analysis of the tumor immune microenvironment. Given that the tumor mutation burden is not available, could you provide guidance on whether this patient is likely to respond to atezolizumab therapy? Please perform a detailed gene expression profiling on the tumor sample to detect biomarkers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have the results, review current peer-reviewed literature to guide your clinical interpretation of the findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae1690-ar-ae16904.pkl. "
BLCA,,,,NR,"I have a white female patient diagnosed with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden (TMB) is not assessable. Based on this data, how might we predict her response to Atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden (TMB) is not assessable. Based on this data, how might we predict her response to Atezolizumab therapy? Please conduct comprehensive gene expression profiling on the tumor sample to identify biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have obtained the results, review the latest peer-reviewed literature to inform your clinical interpretation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae4da2-ar-ae4da27.pkl. "
BLCA,4.0,,excluded,R,"In a White male patient with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile obtained from a ureter biopsy and a tumor mutational burden of 4.0 have been assessed. Would these findings suggest that the patient is likely to respond to atezolizumab therapy?","In a White male patient with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile obtained from a ureter biopsy and a tumor mutational burden of 4.0 have been assessed. Would these findings suggest that the patient is likely to respond to atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor sample, focusing on biomarkers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you obtain these results, review the latest peer-reviewed studies to support your clinical interpretation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aec738-ar-aec7380.pkl. "
BLCA,14.0,2.196078431,inflamed,NR,"For a male Caucasian patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy, what are the implications for his likelihood of responding to Atezolizumab therapy?","For a male Caucasian patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy, what are the implications for his likelihood of responding to Atezolizumab therapy? Please conduct a comprehensive gene expression evaluation of the tumor sample, with particular emphasis on biomarkers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the analysis results, review current peer-reviewed literature to enhance and support your clinical interpretation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/af42c1-ar-af42c15.pkl. "
BLCA,7.0,0.352941176,,NR,"I have a Caucasian male patient with bladder urothelial carcinoma whose tumor mutational burden is 7.0. We obtained a transcriptomic profile of his tumor immune microenvironment from a lung biopsy. Based on these findings, is he likely to benefit from atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma whose tumor mutational burden is 7.0. We obtained a transcriptomic profile of his tumor immune microenvironment from a lung biopsy. Based on these findings, is he likely to benefit from atezolizumab therapy? Please perform a comprehensive gene expression analysis of the tumor sample, specifically evaluating biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review relevant peer-reviewed literature to contextualize and support your clinical interpretation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b0a83e-ar-b0a83e5.pkl. "
BLCA,3.0,0.843137255,inflamed,NR,"I am managing a female patient with bladder urothelial carcinoma, and we obtained a transcriptomic profile of her tumor immune microenvironment from a lung biopsy. Given that her tumor mutation burden is 3.0, do you think she is likely to respond to atezolizumab therapy?","I am managing a female patient with bladder urothelial carcinoma, and we obtained a transcriptomic profile of her tumor immune microenvironment from a lung biopsy. Given that her tumor mutation burden is 3.0, do you think she is likely to respond to atezolizumab therapy? Conduct a thorough gene expression analysis on the tumor sample, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review the relevant peer-reviewed literature to support and refine your clinical interpretation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b0d11d-ar-b0d11db.pkl. "
BLCA,11.0,1.509803922,,R,"In a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 11.0, based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, is there reason to expect a beneficial response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 11.0, based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, is there reason to expect a beneficial response to Atezolizumab therapy? Perform an in-depth gene expression profiling on the tumor sample, specifically examining markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After concluding the analysis, review current peer-reviewed literature to confirm and refine your clinical interpretation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b15ac6-ar-b15ac6e.pkl. "
BLCA,4.0,,excluded,NR,"I have a Caucasian female patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, and her tumor shows a TMB of 4.0 mutations per megabase. Based on these data, what is the likelihood that she will respond to Atezolizumab therapy?","I have a Caucasian female patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, and her tumor shows a TMB of 4.0 mutations per megabase. Based on these data, what is the likelihood that she will respond to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis of the tumor specimen, focusing on markers that indicate the presence and activity of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you complete this analysis, review recent peer-reviewed literature to validate and, if necessary, refine your clinical interpretation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b15ad0-ar-b15ad09.pkl. "
BLCA,,,,NR,"For a Caucasian female patient with bladder urothelial carcinoma, given that the transcriptomic profile of the tumor immune microenvironment from her bladder biopsy is available but the tumor mutational burden is not determined, how might these findings inform her potential response to atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma, given that the transcriptomic profile of the tumor immune microenvironment from her bladder biopsy is available but the tumor mutational burden is not determined, how might these findings inform her potential response to atezolizumab therapy? Please perform an in-depth gene expression analysis of the tumor sample with a focus on identifying markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review recent peer-reviewed literature to confirm your findings and adjust your clinical interpretation if necessary.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b2e4a0-ar-b2e4a08.pkl. "
BLCA,,0.862745098,desert,R,"In a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutation burden (TMB) is unavailable. Based on these findings, what is the likelihood that the patient will respond to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutation burden (TMB) is unavailable. Based on these findings, what is the likelihood that the patient will respond to atezolizumab therapy? Please conduct a thorough gene expression analysis on the tumor sample, specifically evaluating markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have completed the analysis, review the most recent peer-reviewed literature to confirm your findings and adjust your clinical interpretation if needed.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b2f1d0-ar-b2f1d0e.pkl. "
BLCA,18.0,,desert,R,"For a white male patient with bladder urothelial carcinoma (BLCA) presenting a tumor mutation burden of 18.0 and available transcriptomic profiling of the tumor immune microenvironment from a previous biopsy, is there evidence to suggest he will respond favorably to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) presenting a tumor mutation burden of 18.0 and available transcriptomic profiling of the tumor immune microenvironment from a previous biopsy, is there evidence to suggest he will respond favorably to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor specimen, focusing on markers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing this analysis, review the latest peer-reviewed literature to verify your findings and update your clinical assessment accordingly.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b3c022-ar-b3c0229.pkl. "
BLCA,19.0,,excluded,R,"I have a white male patient with bladder urothelial carcinoma who has a tumor mutational burden (TMB) of 19.0. We also have transcriptomic data from a bladder biopsy that profiles his tumor immune microenvironment. Based on these findings, is he likely to respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma who has a tumor mutational burden (TMB) of 19.0. We also have transcriptomic data from a bladder biopsy that profiles his tumor immune microenvironment. Based on these findings, is he likely to respond to atezolizumab therapy? Please perform a detailed gene expression profiling on the tumor sample, concentrating on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once completed, consult the most recent peer-reviewed research to confirm your findings and adjust your clinical evaluation as needed.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b419a8-ar-b419a8f.pkl. "
BLCA,35.0,,excluded,R,"I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment was characterized using transcriptomic profiling from a bladder biopsy, and his tumor mutational burden is 35. Based on these findings, can we expect a favorable response to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment was characterized using transcriptomic profiling from a bladder biopsy, and his tumor mutational burden is 35. Based on these findings, can we expect a favorable response to atezolizumab therapy? Please complete a comprehensive gene expression analysis on the tumor sample, specifically targeting markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the results, review the latest peer-reviewed literature to validate your findings and update your clinical assessment as necessary.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b470eb-ar-b470eb8.pkl. "
BLCA,5.0,,inflamed,NR,"A white male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden (TMB) of 5.0, and we have transcriptomic profiling data of his tumor immune microenvironment from a kidney biopsy. Based on these findings, is he likely to respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden (TMB) of 5.0, and we have transcriptomic profiling data of his tumor immune microenvironment from a kidney biopsy. Based on these findings, is he likely to respond to Atezolizumab therapy? Perform a full gene expression profiling on the tumor sample, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have the results, review current, peer-reviewed literature to confirm your findings and adjust your clinical assessment as needed.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b4c7a0-ar-b4c7a00.pkl. "
BLCA,5.0,0.333333333,desert,NR,"I have a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0. We also have transcriptomic data from a bladder biopsy detailing the tumor immune microenvironment. Based on these findings, is he likely to benefit from Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0. We also have transcriptomic data from a bladder biopsy detailing the tumor immune microenvironment. Based on these findings, is he likely to benefit from Atezolizumab therapy? Conduct comprehensive gene expression profiling on the tumor sample, specifically targeting markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the data are obtained, review the latest peer-reviewed research to verify your results and, if necessary, update your clinical evaluation based on these findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b8070b-ar-b8070b7.pkl. "
BLCA,16.0,3.764705882,inflamed,NR,Will a white male patient with bladder urothelial carcinoma—whose tumor immune microenvironment has been profiled via transcriptomic analysis from a bladder biopsy and who has a tumor mutational burden of 16.0—likely respond to Atezolizumab therapy?,"Will a white male patient with bladder urothelial carcinoma—whose tumor immune microenvironment has been profiled via transcriptomic analysis from a bladder biopsy and who has a tumor mutational burden of 16.0—likely respond to Atezolizumab therapy? Perform a detailed gene expression analysis on the tumor sample, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the data, compare your findings with the most current peer-reviewed research, and update your clinical interpretation as needed based on this evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b8101c-ar-b8101c5.pkl. "
BLCA,8.0,0.882352941,excluded,NR,"A patient with bladder urothelial carcinoma has a tumor mutation burden of 8.0. We also have the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, is the patient likely to respond to atezolizumab therapy?","A patient with bladder urothelial carcinoma has a tumor mutation burden of 8.0. We also have the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, is the patient likely to respond to atezolizumab therapy? Conduct a comprehensive gene expression analysis of the tumor sample, specifically targeting markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have the results, review and compare them against the latest peer-reviewed research, and revise your clinical interpretation accordingly.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b963dd-ar-b963dda.pkl. "
BLCA,5.0,0.901960784,inflamed,NR,"For our white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0 and for whom we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, is there evidence to suggest that he would benefit from treatment with atezolizumab?","For our white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0 and for whom we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, is there evidence to suggest that he would benefit from treatment with atezolizumab? Perform a detailed gene expression analysis of the tumor sample, focusing specifically on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the results, review them in the context of the most recent peer-reviewed research and update your clinical interpretation based on this comparative analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ba1a34-ar-ba1a34b.pkl. "
BLCA,5.0,,excluded,NR,"I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy has been conducted, and her tumor mutational burden is 5.0. Based on these findings, could she be a suitable candidate for Atezolizumab therapy?","I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy has been conducted, and her tumor mutational burden is 5.0. Based on these findings, could she be a suitable candidate for Atezolizumab therapy? Please conduct a comprehensive gene expression analysis of the tumor sample, specifically examining markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the findings in light of the latest evidence from peer-reviewed research, and update your clinical interpretation as needed.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ba7176-ar-ba7176a.pkl. "
BLCA,7.0,0.745098039,desert,NR,"In a white female patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 7.0 based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that she will respond favorably to atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 7.0 based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that she will respond favorably to atezolizumab therapy? Please perform a thorough gene expression analysis of the tumor sample, paying close attention to markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, compare your results with current findings in peer-reviewed literature to refine your clinical interpretation as needed.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bc8dc3-ar-bc8dc3a.pkl. "
BLCA,,,excluded,NR,"I have a Caucasian male patient with bladder urothelial carcinoma, and we obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. With the tumor mutational burden being unavailable, what is the likely response to Atezolizumab therapy in this case?","I have a Caucasian male patient with bladder urothelial carcinoma, and we obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. With the tumor mutational burden being unavailable, what is the likely response to Atezolizumab therapy in this case? Please conduct a comprehensive gene expression analysis of the tumor sample, with particular attention to markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining your results, compare them with the latest findings in reputable peer-reviewed literature to refine your clinical interpretation as warranted.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bcb07b-ar-bcb07ba.pkl. "
BLCA,9.0,,desert,NR,"My Caucasian patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden (TMB) of 9.0, and we have obtained transcriptomic data from a bladder biopsy detailing the tumor immune microenvironment. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","My Caucasian patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden (TMB) of 9.0, and we have obtained transcriptomic data from a bladder biopsy detailing the tumor immune microenvironment. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Please perform an in-depth gene expression analysis on the tumor sample, focusing specifically on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review your findings against recent, peer-reviewed literature to ensure your clinical interpretation remains current and evidence-based.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bcbc79-ar-bcbc795.pkl. "
BLCA,20.0,1.254901961,inflamed,NR,"For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile indicates a tumor mutational burden of 20.0, what is the expected likelihood of a favorable response to atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile indicates a tumor mutational burden of 20.0, what is the expected likelihood of a favorable response to atezolizumab therapy? Conduct a comprehensive gene expression analysis of the tumor sample, focusing on identifying markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have the results, compare your findings with the latest evidence from peer-reviewed literature to ensure your clinical interpretation is both current and scientifically robust.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bda79f-ar-bda79f9.pkl. "
BLCA,10.0,0.784313725,excluded,NR,"A white female patient with bladder urothelial carcinoma (BLCA) has a tumor immune microenvironment transcriptomic profile from a lymph node biopsy and a tumor mutational burden (TMB) of 10. Based on these findings, should we anticipate a favorable response to Atezolizumab therapy?","A white female patient with bladder urothelial carcinoma (BLCA) has a tumor immune microenvironment transcriptomic profile from a lymph node biopsy and a tumor mutational burden (TMB) of 10. Based on these findings, should we anticipate a favorable response to Atezolizumab therapy? Please perform a detailed gene expression profiling of the tumor sample, specifically targeting markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining your results, review them in the context of the most recent peer-reviewed studies to ensure that our clinical interpretation remains both current and scientifically accurate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/be83ea-ar-be83eae.pkl. "
BLCA,35.0,3.745098039,excluded,R,"In a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 35.0, with transcriptomic profiling from a bladder biopsy assessing the tumor immune microenvironment, is there evidence supporting the effectiveness of Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 35.0, with transcriptomic profiling from a bladder biopsy assessing the tumor immune microenvironment, is there evidence supporting the effectiveness of Atezolizumab therapy? Please conduct a comprehensive gene expression analysis of the tumor sample, concentrating on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have the results, compare them with insights from the latest peer-reviewed literature to confirm that our clinical interpretation is both current and evidence-based.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bf1a3a-ar-bf1a3ae.pkl. "
BLCA,6.0,1.450980392,excluded,NR,"I have a Caucasian female patient with bladder urothelial carcinoma (BLCA) whose transcriptomic profiling from a bladder biopsy indicates a tumor mutational burden (TMB) of 6.0. Based on this data, is it likely that she will respond to Atezolizumab therapy?","I have a Caucasian female patient with bladder urothelial carcinoma (BLCA) whose transcriptomic profiling from a bladder biopsy indicates a tumor mutational burden (TMB) of 6.0. Based on this data, is it likely that she will respond to Atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor sample, focusing on markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the results, compare them with findings from the latest peer-reviewed research to ensure our clinical interpretation remains current and evidence-based.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bfdffb-ar-bfdffb9.pkl. "
BLCA,3.0,0.294117647,desert,NR,"My white female patient with bladder urothelial carcinoma (BLCA) presents with a tumor mutation burden (TMB) of 3.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, how likely is she to respond to Atezolizumab therapy?","My white female patient with bladder urothelial carcinoma (BLCA) presents with a tumor mutation burden (TMB) of 3.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, how likely is she to respond to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor sample with a focus on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, compare the results with data from the most recent peer-reviewed studies to ensure that our clinical interpretation is both current and evidence-based.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0d625-ar-c0d625a.pkl. "
BLCA,5.0,1.176470588,desert,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. His tumor’s immune microenvironment has been profiled using transcriptomic analysis from a bladder biopsy, and his TMB is 5.0. Based on these findings, is he likely to respond to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. His tumor’s immune microenvironment has been profiled using transcriptomic analysis from a bladder biopsy, and his TMB is 5.0. Based on these findings, is he likely to respond to Atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor sample, focusing on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review and compare your results with the latest peer-reviewed studies to ensure that our clinical interpretations remain current and evidence-based.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0da5d-ar-c0da5d4.pkl. "
BLCA,5.0,0.960784314,desert,NR,"A Caucasian male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 5.0. Transcriptomic profiling of the tumor immune microenvironment was performed using nanobiopsy. Based on these findings, is there an expectation that the patient will respond to atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 5.0. Transcriptomic profiling of the tumor immune microenvironment was performed using nanobiopsy. Based on these findings, is there an expectation that the patient will respond to atezolizumab therapy? Conduct a comprehensive gene expression analysis of the tumor sample, specifically examining markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, please compare these findings with the most recent peer-reviewed literature to ensure that our evaluations are up-to-date and grounded in robust evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0ef41-ar-c0ef41a.pkl. "
BLCA,5.0,1.098039216,excluded,R,"For a white male patient with bladder urothelial carcinoma, a tumor mutational burden of 5.0, and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, is there clinical evidence to suggest that he would respond favorably to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, a tumor mutational burden of 5.0, and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, is there clinical evidence to suggest that he would respond favorably to Atezolizumab therapy? Perform a detailed gene expression analysis on the tumor sample, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the results, compare your findings with the latest peer-reviewed studies to ensure our assessments are current and evidence-based.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c1251c-ar-c1251c7.pkl. "
BLCA,5.0,1.411764706,excluded,R,"For a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, is there evidence to suggest that Atezolizumab therapy would be effective?","For a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, is there evidence to suggest that Atezolizumab therapy would be effective? Conduct a comprehensive gene expression analysis on the tumor sample, specifically assessing markers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have the results, compare them with the most recent peer-reviewed research to confirm that our findings are up-to-date and consistent with current evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c1b27b-ar-c1b27bc.pkl. "
BLCA,,,excluded,R,"In a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment has been completed, but the tumor mutation burden is reported as ""nan."" Based on this information, how can we interpret the potential response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment has been completed, but the tumor mutation burden is reported as ""nan."" Based on this information, how can we interpret the potential response to Atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor sample, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have the data, review the latest peer-reviewed research to ensure our findings are aligned with current evidence and remain up-to-date.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c2a182-ar-c2a1820.pkl. "
BLCA,3.0,0.196078431,desert,NR,"I have a patient with bladder urothelial carcinoma whose tumor biopsy transcriptomic profiling of the immune microenvironment is available and has a TMB of 3.0. Based on these findings, is it likely that the patient will respond to Atezolizumab therapy?","I have a patient with bladder urothelial carcinoma whose tumor biopsy transcriptomic profiling of the immune microenvironment is available and has a TMB of 3.0. Based on these findings, is it likely that the patient will respond to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor sample, with a specific focus on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After obtaining the results, review the most recent peer-reviewed literature to ensure that our data interpretation is consistent with current scientific standards and evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c57ead-ar-c57eadb.pkl. "
BLCA,10.0,,desert,NR,"I have a white male patient with bladder urothelial carcinoma. His tumor mutation burden is 10, and we have obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy. Based on these findings, what is your assessment regarding his potential response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. His tumor mutation burden is 10, and we have obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy. Based on these findings, what is your assessment regarding his potential response to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor sample, focusing particularly on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the latest peer-reviewed literature to confirm that our data interpretation aligns with up-to-date scientific evidence and standards.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c69253-ar-c692536.pkl. "
BLCA,3.0,0.450980392,excluded,NR,"A Caucasian male patient with bladder urothelial carcinoma (BLCA) has undergone transcriptomic profiling of his tumor immune microenvironment from a lymph node biopsy. Given his tumor mutational burden (TMB) of 3.0, what is the likelihood that he will respond to Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma (BLCA) has undergone transcriptomic profiling of his tumor immune microenvironment from a lymph node biopsy. Given his tumor mutational burden (TMB) of 3.0, what is the likelihood that he will respond to Atezolizumab therapy? Please conduct a detailed gene expression analysis on the tumor sample, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review the latest peer-reviewed literature to ensure that our data interpretation is consistent with the most current scientific evidence and standards.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c6eff0-ar-c6eff05.pkl. "
BLCA,3.0,0.607843137,inflamed,R,"In a white male patient with bladder urothelial carcinoma, a tumor mutation burden of 3.0, and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a tumor mutation burden of 3.0, and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a response to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor tissue, concentrating on biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the most recent peer-reviewed studies to verify that our data interpretation is consistent with current scientific findings and standards.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c919ae-ar-c919aeb.pkl. "
BLCA,11.0,1.352941176,inflamed,NR,"I have a Black/African American female patient with bladder urothelial carcinoma (BLCA). Transcriptomic profiling of her tumor immune microenvironment from a lung biopsy shows a tumor mutational burden (TMB) of 11.0. Based on this data, is she likely to respond to atezolizumab therapy?","I have a Black/African American female patient with bladder urothelial carcinoma (BLCA). Transcriptomic profiling of her tumor immune microenvironment from a lung biopsy shows a tumor mutational burden (TMB) of 11.0. Based on this data, is she likely to respond to atezolizumab therapy? Please conduct a detailed gene expression profiling on the tumor sample, with a focus on biomarkers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is completed, review the latest peer-reviewed studies to confirm that our interpretation of the data aligns with current scientific standards.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cabb6d-ar-cabb6d5.pkl. "
BLCA,,0.843137255,desert,NR,"For a Caucasian male patient with bladder urothelial carcinoma, given that the transcriptomic analysis of the tumor immune microenvironment from his lymph node biopsy shows an undetermined tumor mutational burden, is there evidence to suggest that he would respond to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, given that the transcriptomic analysis of the tumor immune microenvironment from his lymph node biopsy shows an undetermined tumor mutational burden, is there evidence to suggest that he would respond to Atezolizumab therapy? Please perform comprehensive gene expression profiling on the tumor sample, specifically targeting biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the latest peer-reviewed literature to ensure our data interpretations meet current scientific standards.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cb132b-ar-cb132b0.pkl. "
BLCA,,,,NR,"A Caucasian male patient with bladder urothelial carcinoma has undergone liver biopsy for transcriptomic profiling of the tumor immune microenvironment, and currently, his tumor mutation burden data is not available. Based on this information, what is the likelihood of a favorable response to Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has undergone liver biopsy for transcriptomic profiling of the tumor immune microenvironment, and currently, his tumor mutation burden data is not available. Based on this information, what is the likelihood of a favorable response to Atezolizumab therapy? Please conduct a detailed gene expression analysis on the tumor tissue, focusing primarily on biomarkers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review the latest peer-reviewed studies to confirm that our interpretations are in line with current scientific consensus.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cc4675-ar-cc4675f.pkl. "
BLCA,26.0,4.960784314,inflamed,R,"For a white female patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy and a tumor mutation burden of 26.0, is there evidence to suggest that she is likely to respond to atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy and a tumor mutation burden of 26.0, is there evidence to suggest that she is likely to respond to atezolizumab therapy? Please perform a comprehensive gene expression analysis of the tumor tissue, with a focus on identifying biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have completed this analysis, carefully review the most recent peer-reviewed literature to ensure that our interpretations are consistent with current scientific consensus.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cc7a42-ar-cc7a42d.pkl. "
BLCA,14.0,0.843137255,inflamed,NR,"A white male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 14.0, and we have a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. Could his molecular and immunologic profile indicate a likelihood of response to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 14.0, and we have a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. Could his molecular and immunologic profile indicate a likelihood of response to Atezolizumab therapy? Please conduct a thorough gene expression analysis of the tumor tissue, with particular attention to biomarkers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing this analysis, review the latest peer-reviewed literature to verify that our findings are in line with current scientific standards.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ce39dd-ar-ce39dd7.pkl. "
BLCA,,,excluded,NR,"For a white male patient with bladder urothelial carcinoma who has undergone transcriptomic profiling of the tumor immune microenvironment via lung biopsy, and with unavailable tumor mutational burden data, how likely is it that he will respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has undergone transcriptomic profiling of the tumor immune microenvironment via lung biopsy, and with unavailable tumor mutational burden data, how likely is it that he will respond to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor tissue, specifically evaluating biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have completed the analysis, review the latest peer-reviewed literature to ensure that our results meet current scientific standards.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cf018f-ar-cf018fe.pkl. "
BLCA,4.0,0.764705882,desert,R,"For a Caucasian female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 4.0 and a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, what is the expected response to Atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 4.0 and a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, what is the expected response to Atezolizumab therapy? Please perform a complete gene expression profiling on the tumor tissue, focusing on biomarkers relevant to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review the most recent peer-reviewed studies to ensure that our findings align with current scientific standards.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d02712-ar-d027124.pkl. "
BLCA,3.0,0.607843137,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutation burden (TMB) of 3.0. We recently obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, how likely is it that the patient will respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutation burden (TMB) of 3.0. We recently obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, how likely is it that the patient will respond to Atezolizumab therapy? Please perform a full gene expression analysis on the tumor tissue, specifically targeting biomarkers linked to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review the latest peer-reviewed literature to confirm that our findings are consistent with current scientific standards.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d135d5-ar-d135d58.pkl. "
BLCA,22.0,,,NR,"For a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 22.0, based on the transcriptomic profile of his tumor immune microenvironment obtained from a bladder biopsy, what is his likelihood of responding to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 22.0, based on the transcriptomic profile of his tumor immune microenvironment obtained from a bladder biopsy, what is his likelihood of responding to atezolizumab therapy? Please conduct a comprehensive gene expression profile on the tumor tissue, focusing on biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After the analysis, review recent peer-reviewed publications to ensure that our findings align with current scientific standards.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d1bd63-ar-d1bd637.pkl. "
BLCA,,,,NR,"My white male patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his TMB data is unavailable. Based on these findings, do you anticipate he would respond to Atezolizumab therapy?","My white male patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his TMB data is unavailable. Based on these findings, do you anticipate he would respond to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor tissue, specifically targeting biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review recent peer-reviewed literature to verify that our results conform to current scientific standards.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d215b5-ar-d215b50.pkl. "
BLCA,3.0,0.490196078,desert,NR,"For a white female patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy and a tumor mutational burden of 3.0, what is the likelihood that she will benefit from Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy and a tumor mutational burden of 3.0, what is the likelihood that she will benefit from Atezolizumab therapy? Please conduct a thorough gene expression analysis of the tumor tissue, focusing on biomarkers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review recent peer-reviewed literature to ensure that our findings meet current scientific standards.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d2492b-ar-d2492b2.pkl. "
BLCA,62.0,10.01960784,excluded,R,"For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 62.0 and whose tumor immune microenvironment transcriptomic profile was obtained via kidney biopsy, could we expect a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 62.0 and whose tumor immune microenvironment transcriptomic profile was obtained via kidney biopsy, could we expect a favorable response to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor tissue, with particular attention to biomarkers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, review recent peer-reviewed literature to confirm that our findings adhere to current scientific standards.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d35318-ar-d353181.pkl. "
BLCA,14.0,0.784313725,excluded,R,"We have a patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled through transcriptomic analysis from a prior biopsy. Given a tumor mutational burden of 14.0, can we expect a favorable response to Atezolizumab therapy?","We have a patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled through transcriptomic analysis from a prior biopsy. Given a tumor mutational burden of 14.0, can we expect a favorable response to Atezolizumab therapy? Conduct a thorough gene expression analysis of the tumor tissue, focusing specifically on biomarkers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, review recent peer-reviewed research to ensure that our results are in line with current scientific standards.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d36012-ar-d360128.pkl. "
BLCA,7.0,1.568627451,excluded,R,"In a white male patient with bladder urothelial carcinoma, where a lymph node biopsy has been used to profile the tumor immune microenvironment and the tumor mutational burden is 7.0, how likely is it that he will respond favorably to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, where a lymph node biopsy has been used to profile the tumor immune microenvironment and the tumor mutational burden is 7.0, how likely is it that he will respond favorably to Atezolizumab therapy? Please perform a comprehensive gene expression profiling of the tumor tissue, focusing on biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have completed the analysis, review the latest peer-reviewed literature to confirm that our findings align with current scientific standards.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d3bd67-ar-d3bd679.pkl. "
BLCA,15.0,1.882352941,inflamed,R,"I have a patient with bladder urothelial carcinoma (BLCA) with a tumor mutation burden of 15. Based on the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the likelihood that this patient will respond to Atezolizumab therapy?","I have a patient with bladder urothelial carcinoma (BLCA) with a tumor mutation burden of 15. Based on the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the likelihood that this patient will respond to Atezolizumab therapy? Please conduct an in-depth gene expression analysis of the tumor sample, concentrating particularly on biomarkers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, verify that our results align with the latest peer-reviewed research and current scientific standards.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d43f89-ar-d43f893.pkl. "
BLCA,5.0,0.529411765,excluded,NR,"Our white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment obtained from a kidney biopsy, and his tumor mutation burden is 5.0. Based on these findings, is he likely to respond to Atezolizumab therapy?","Our white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment obtained from a kidney biopsy, and his tumor mutation burden is 5.0. Based on these findings, is he likely to respond to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor sample, with a specific emphasis on biomarkers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once the analysis is complete, ensure that the results are consistent with the latest findings from peer-reviewed research and adhere to current scientific guidelines.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d4c083-ar-d4c0837.pkl. "
BLCA,,0.196078431,inflamed,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. We obtained transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy, but his tumor mutational burden is not available. Based on these data, can we predict whether he is likely to respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. We obtained transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy, but his tumor mutational burden is not available. Based on these data, can we predict whether he is likely to respond to Atezolizumab therapy? Please conduct a detailed gene expression analysis of the tumor sample, focusing on biomarkers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. After completing the analysis, verify that the findings align with the most recent evidence from peer-reviewed studies and conform to current scientific protocols.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d636e3-ar-d636e34.pkl. "
BLCA,,,excluded,NR,"In a white female patient with bladder urothelial carcinoma, where the tumor's transcriptomic profile (from a ureter biopsy) has been assessed but the tumor mutational burden is not available, can we expect a favorable response to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, where the tumor's transcriptomic profile (from a ureter biopsy) has been assessed but the tumor mutational burden is not available, can we expect a favorable response to Atezolizumab therapy? Perform a comprehensive gene expression profiling of the tumor sample, emphasizing biomarkers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once completed, ensure that the results are consistent with the latest evidence from peer-reviewed literature and adhere to current established scientific protocols.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d697ba-ar-d697ba7.pkl. "
BLCA,24.0,,inflamed,R,I have a Caucasian male patient with bladder urothelial carcinoma (BLCA) whose tumor transcriptomic profile from a bladder biopsy shows significant immune microenvironment activity and a tumor mutational burden of 24. Could these findings indicate a favorable response to atezolizumab therapy?,"I have a Caucasian male patient with bladder urothelial carcinoma (BLCA) whose tumor transcriptomic profile from a bladder biopsy shows significant immune microenvironment activity and a tumor mutational burden of 24. Could these findings indicate a favorable response to atezolizumab therapy? Please perform a detailed gene expression analysis of the tumor sample, focusing on biomarkers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that the methodology and findings are consistent with the latest peer-reviewed evidence and follow current scientific protocols.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d7d57e-ar-d7d57ee.pkl. "
BLCA,,1.411764706,desert,NR,"For a Caucasian male patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment obtained from bladder biopsy. However, the tumor mutational burden (TMB) value is not available. Based on this information, what is the likelihood of a response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment obtained from bladder biopsy. However, the tumor mutational burden (TMB) value is not available. Based on this information, what is the likelihood of a response to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis of the tumor sample, paying particular attention to biomarkers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that your methods and results are in line with the most current peer-reviewed literature and adhere to established scientific protocols.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d86389-ar-d86389d.pkl. "
BLCA,8.0,0.725490196,desert,NR,"In a White male patient with bladder urothelial carcinoma (BLCA) who has a tumor immune microenvironment profile obtained from a ureter biopsy and a tumor mutational burden (TMB) of 8.0 mutations per megabase, what is the likelihood of a favorable response to atezolizumab therapy?","In a White male patient with bladder urothelial carcinoma (BLCA) who has a tumor immune microenvironment profile obtained from a ureter biopsy and a tumor mutational burden (TMB) of 8.0 mutations per megabase, what is the likelihood of a favorable response to atezolizumab therapy? Please perform a detailed gene expression profiling on the tumor sample, with a focus on identifying markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that your methodology and findings are consistent with the latest peer-reviewed research and adhere to established scientific protocols.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d98bac-ar-d98bac0.pkl. "
BLCA,4.0,0.274509804,,NR,"In a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 4.0, and for whom we have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, is there evidence to suggest that he would respond to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 4.0, and for whom we have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, is there evidence to suggest that he would respond to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor specimen, specifically targeting markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that your approach and results align with the most current peer-reviewed research and adhere strictly to established scientific protocols.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/da4d89-ar-da4d892.pkl. "
BLCA,14.0,2.921568627,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma, possessing a tumor immune microenvironment transcriptomic profile from a bladder biopsy and a TMB of 14.0, is there evidence to suggest that this patient will respond to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, possessing a tumor immune microenvironment transcriptomic profile from a bladder biopsy and a TMB of 14.0, is there evidence to suggest that this patient will respond to Atezolizumab therapy? Please perform a detailed gene expression profiling on the tumor specimen, focusing on markers linked to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that your methodology and findings are consistent with the latest peer-reviewed research and follow established scientific protocols.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dab9ca-ar-dab9ca8.pkl. "
BLCA,5.0,0.666666667,excluded,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) with a tumor mutation burden (TMB) of 5.0. Based on the transcriptomic profile of the tumor immune microenvironment obtained from his bladder biopsy, can we predict his potential response to atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) with a tumor mutation burden (TMB) of 5.0. Based on the transcriptomic profile of the tumor immune microenvironment obtained from his bladder biopsy, can we predict his potential response to atezolizumab therapy? Conduct a comprehensive gene expression analysis on the tumor specimen, concentrating on markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Please ensure that all methodologies are up-to-date with the latest peer-reviewed research and adhere strictly to established scientific protocols.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dad5c2-ar-dad5c29.pkl. "
BLCA,10.0,0.509803922,excluded,NR,"For a white male patient with bladder urothelial carcinoma, whose tumor biopsy reveals a transcriptomic profile of the immune microenvironment and a tumor mutational burden of 10.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose tumor biopsy reveals a transcriptomic profile of the immune microenvironment and a tumor mutational burden of 10.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor specimen. Focus particularly on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure all methodologies are aligned with current peer-reviewed research and that you strictly follow established scientific protocols.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/db3f50-ar-db3f50c.pkl. "
BLCA,,1.431372549,excluded,NR,"A white male patient with bladder urothelial carcinoma has undergone a kidney biopsy, and we obtained a transcriptomic profile of the tumor immune microenvironment. The tumor mutation burden (TMB) is reported as ""nan"". Based on these findings, would you expect the patient to respond to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has undergone a kidney biopsy, and we obtained a transcriptomic profile of the tumor immune microenvironment. The tumor mutation burden (TMB) is reported as ""nan"". Based on these findings, would you expect the patient to respond to atezolizumab therapy? Please conduct a thorough gene expression profiling of the tumor specimen, paying special attention to markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that all analytical methods utilized are consistent with the latest evidence from peer-reviewed studies and adhere strictly to established scientific protocols.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dcae54-ar-dcae54f.pkl. "
BLCA,,,,NR,"A Caucasian male patient with bladder urothelial carcinoma (BLCA) has had a lymph node biopsy that provided a transcriptomic profile of his tumor immune microenvironment. Given that his tumor mutation burden (TMB) is not available, how might we predict his likelihood of responding to atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma (BLCA) has had a lymph node biopsy that provided a transcriptomic profile of his tumor immune microenvironment. Given that his tumor mutation burden (TMB) is not available, how might we predict his likelihood of responding to atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor specimen, specifically evaluating markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that the analytical methods used align with current evidence from recent peer-reviewed studies and adhere strictly to established scientific protocols.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dee101-ar-dee1011.pkl. "
BLCA,19.0,3.235294118,inflamed,NR,"I have a White male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment has been profiled using transcriptomic analysis from a bladder biopsy, and his tumor mutational burden (TMB) is 19.0. Based on these findings, what is his likelihood of responding to Atezolizumab therapy?","I have a White male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment has been profiled using transcriptomic analysis from a bladder biopsy, and his tumor mutational burden (TMB) is 19.0. Based on these findings, what is his likelihood of responding to Atezolizumab therapy? Please conduct a comprehensive gene expression profiling of the tumor sample, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that your methods are in line with the latest evidence from peer-reviewed research and adhere strictly to established scientific protocols.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/df3e42-ar-df3e42c.pkl. "
BLCA,5.0,0.549019608,desert,NR,"In a patient with bladder urothelial carcinoma evaluated via a ureter biopsy revealing the tumor immune microenvironment profile and a tumor mutational burden of 5.0, what is the anticipated likelihood of responding to atezolizumab therapy?","In a patient with bladder urothelial carcinoma evaluated via a ureter biopsy revealing the tumor immune microenvironment profile and a tumor mutational burden of 5.0, what is the anticipated likelihood of responding to atezolizumab therapy? Please perform an in-depth gene expression analysis on the tumor sample, with particular attention to markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that the methodology aligns with the most recent peer-reviewed research and adheres to established scientific protocols.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e07c45-ar-e07c456.pkl. "
BLCA,2.0,,excluded,NR,"In a Caucasian female patient with bladder urothelial carcinoma, based on the transcriptomic profile of the tumor's immune microenvironment and a tumor mutation burden of approximately 2.0, is there evidence to suggest that Atezolizumab therapy would be effective?","In a Caucasian female patient with bladder urothelial carcinoma, based on the transcriptomic profile of the tumor's immune microenvironment and a tumor mutation burden of approximately 2.0, is there evidence to suggest that Atezolizumab therapy would be effective? Please conduct a thorough gene expression profiling analysis of the tumor sample, specifically targeting markers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Utilize methodologies that adhere to the latest peer-reviewed research and follow established scientific protocols.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e0c49e-ar-e0c49ea.pkl. "
BLCA,14.0,2.274509804,inflamed,R,"For a Caucasian patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden (TMB) of 14.0 and a transcriptomic profile from a bladder biopsy detailing the tumor immune microenvironment, can we expect a favorable response to Atezolizumab therapy?","For a Caucasian patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden (TMB) of 14.0 and a transcriptomic profile from a bladder biopsy detailing the tumor immune microenvironment, can we expect a favorable response to Atezolizumab therapy? Please perform a detailed gene expression profile on the tumor sample that specifically examines markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that the analysis is carried out using current, peer-reviewed methodologies and adheres to established scientific protocols.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e1eb5d-ar-e1eb5d9.pkl. "
BLCA,17.0,0.862745098,inflamed,NR,"For a Caucasian female patient with bladder urothelial carcinoma, a tumor mutational burden of 17.0, and a transcriptomic profile of the tumor immune microenvironment obtained via nano-biopsy, what is the likelihood that she will respond to atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma, a tumor mutational burden of 17.0, and a transcriptomic profile of the tumor immune microenvironment obtained via nano-biopsy, what is the likelihood that she will respond to atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor sample, specifically targeting markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that this examination is performed using up-to-date, peer-reviewed methods that comply with established scientific protocols.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e3210d-ar-e3210d3.pkl. "
BLCA,,,,NR,"I have a white male patient with bladder urothelial carcinoma who underwent a bladder biopsy yielding a transcriptomic profile of the tumor's immune microenvironment. His tumor mutational burden is not available. Based on this information, how likely is he to respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma who underwent a bladder biopsy yielding a transcriptomic profile of the tumor's immune microenvironment. His tumor mutational burden is not available. Based on this information, how likely is he to respond to Atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor sample, specifically assessing markers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use current, peer-reviewed methodologies that adhere to established scientific protocols.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e3d426-ar-e3d4266.pkl. "
BLCA,6.0,0.470588235,excluded,NR,"Our white male patient has bladder urothelial carcinoma (BLCA), and his tumor’s transcriptomic profile from a bladder biopsy reveals a tumor mutational burden of 6.0. Based on these findings, is he likely to respond to Atezolizumab therapy?","Our white male patient has bladder urothelial carcinoma (BLCA), and his tumor’s transcriptomic profile from a bladder biopsy reveals a tumor mutational burden of 6.0. Based on these findings, is he likely to respond to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor specimen, focusing on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that you use established, peer-reviewed methods and adhere to current best practices in the field.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e41b1e-ar-e41b1e7.pkl. "
BLCA,9.0,2.176470588,desert,R,"For a white female patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a bladder biopsy shows a tumor mutation burden of 9, how likely is it that she will respond to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a bladder biopsy shows a tumor mutation burden of 9, how likely is it that she will respond to Atezolizumab therapy? Please perform a detailed gene expression analysis on the tumor tissue, concentrating on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use validated, peer-reviewed methodologies and follow the latest best practice guidelines in the field.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e50d15-ar-e50d15f.pkl. "
BLCA,5.0,0.098039216,excluded,NR,"In our white female patient with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood that she will respond to Atezolizumab therapy?","In our white female patient with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood that she will respond to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis on the tumor tissue. Specifically, assess markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that you use validated, peer-reviewed techniques and adhere to the most recent best-practice guidelines in the field.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e56c96-ar-e56c96c.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). A liver biopsy provided a transcriptomic profile of his tumor immune microenvironment, and his tumor mutation burden (TMB) is 5.0. Based on these findings, is he likely to respond to atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). A liver biopsy provided a transcriptomic profile of his tumor immune microenvironment, and his tumor mutation burden (TMB) is 5.0. Based on these findings, is he likely to respond to atezolizumab therapy? Please perform a thorough gene expression profiling on the tumor sample. In particular, evaluate the expression of markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that you use rigorously validated, peer-reviewed techniques and follow the latest best practice guidelines in the field.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e5bc41-ar-e5bc417.pkl. "
BLCA,,,desert,R,"For my white male patient with bladder urothelial carcinoma (BLCA), we have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but his tumor mutation burden (TMB) is reported as ""nan."" Based on this molecular profile, can we predict whether he is likely to respond to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA), we have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but his tumor mutation burden (TMB) is reported as ""nan."" Based on this molecular profile, can we predict whether he is likely to respond to Atezolizumab therapy? Perform comprehensive gene expression analysis on the tumor specimen, focusing specifically on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use rigorously validated, peer-reviewed methods and adhere to the latest best practice guidelines throughout the process.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e71235-ar-e712352.pkl. "
BLCA,,,,NR,"In a white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy; however, the tumor mutational burden was not determined. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy; however, the tumor mutational burden was not determined. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy? Conduct a thorough gene expression profiling of the tumor sample. Please emphasize markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure you employ validated, peer-reviewed methods and follow current clinical guidelines throughout the process.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7bcab-ar-e7bcab0.pkl. "
BLCA,7.0,1.37254902,inflamed,NR,"We have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile was obtained via kidney biopsy. With a tumor mutational burden of 7.0, is he likely to respond favorably to atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile was obtained via kidney biopsy. With a tumor mutational burden of 7.0, is he likely to respond favorably to atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor sample, specifically evaluating markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that all methods used are rigorously validated, peer-reviewed, and in full compliance with current clinical guidelines.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7bf6c-ar-e7bf6c0.pkl. "
BLCA,1.0,0.196078431,inflamed,NR,"In a Caucasian patient with bladder urothelial carcinoma who has a tumor mutation burden of 1.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, is there an expectation for a positive response to Atezolizumab therapy?","In a Caucasian patient with bladder urothelial carcinoma who has a tumor mutation burden of 1.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, is there an expectation for a positive response to Atezolizumab therapy? Please conduct a thorough gene expression analysis of the tumor sample, focusing on markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Kindly ensure that all methodologies employed are rigorously validated, supported by peer-reviewed literature, and fully adhere to the latest clinical guidelines.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7e4f7-ar-e7e4f7c.pkl. "
BLCA,,,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) and have obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. Given that his tumor mutation burden (TMB) is not available, can we predict whether he will respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) and have obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. Given that his tumor mutation burden (TMB) is not available, can we predict whether he will respond to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor sample, concentrating on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that all techniques used are rigorously validated, supported by current peer-reviewed studies, and fully compliant with the latest clinical guidelines.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e9475f-ar-e9475f7.pkl. "
BLCA,6.0,1.019607843,excluded,NR,"In a Caucasian patient with bladder urothelial carcinoma, whose bladder biopsy shows a transcriptomic profile of the tumor immune microenvironment with a TMB of 6.0, is atezolizumab therapy likely to be effective?","In a Caucasian patient with bladder urothelial carcinoma, whose bladder biopsy shows a transcriptomic profile of the tumor immune microenvironment with a TMB of 6.0, is atezolizumab therapy likely to be effective? Please conduct a detailed gene expression analysis on the tumor sample with an emphasis on identifying markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Make sure to use rigorously validated techniques that are supported by the latest peer-reviewed research and comply with current clinical guidelines.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e94c30-ar-e94c30c.pkl. "
BLCA,3.0,0.705882353,excluded,NR,"I have a white female patient with bladder urothelial carcinoma. We recently obtained the transcriptomic profile of her tumor microenvironment from a bladder biopsy, and her tumor mutation burden is 3.0. Based on these findings, is she likely to respond to Atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma. We recently obtained the transcriptomic profile of her tumor microenvironment from a bladder biopsy, and her tumor mutation burden is 3.0. Based on these findings, is she likely to respond to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor sample, focusing particularly on the detection of markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that all methodologies used are rigorously validated, adhere to current clinical guidelines, and are supported by up-to-date peer-reviewed research.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e97af0-ar-e97af0f.pkl. "
BLCA,7.0,1.333333333,desert,NR,"For a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 7.0, based on the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 7.0, based on the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Please conduct a thorough gene expression evaluation of the tumor specimen. This analysis should specifically target markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. It is important that all techniques used are properly validated, conform to the latest clinical guidelines, and are corroborated by current, peer-reviewed literature.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e9ae8b-ar-e9ae8be.pkl. "
BLCA,14.0,2.764705882,inflamed,R,"For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 14 and transcriptomic profiling available from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 14 and transcriptomic profiling available from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor tissue, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that all methodologies applied are validated, align with current clinical guidelines, and are supported by the most recent peer-reviewed studies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eaa477-ar-eaa477a.pkl. "
BLCA,2.0,0.058823529,excluded,NR,"My white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment obtained from a kidney biopsy and a Tumor Mutational Burden (TMB) of 2.0. Based on these findings, is he likely to respond to Atezolizumab therapy?","My white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment obtained from a kidney biopsy and a Tumor Mutational Burden (TMB) of 2.0. Based on these findings, is he likely to respond to Atezolizumab therapy? Conduct a detailed gene expression profiling of the tumor tissue, with a particular focus on identifying markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Please ensure that the techniques utilized are thoroughly validated, adhere to current clinical guidelines, and are supported by the latest peer-reviewed research.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eb2962-ar-eb29625.pkl. "
BLCA,,,,NR,"I have a Caucasian male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of his tumor’s immune microenvironment from a bladder biopsy, but the tumor mutation burden is not available. Based on this information, what is the likelihood that he will respond to atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of his tumor’s immune microenvironment from a bladder biopsy, but the tumor mutation burden is not available. Based on this information, what is the likelihood that he will respond to atezolizumab therapy? Perform a comprehensive gene expression analysis on the tumor tissue, emphasizing the detection of markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use validated methodologies that comply with current clinical guidelines and are supported by the latest peer-reviewed research.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eb587a-ar-eb587a6.pkl. "
BLCA,,,,NR,"A Caucasian male patient with bladder urothelial carcinoma has undergone a lymph node biopsy with transcriptomic profiling of the tumor immune microenvironment. Given that the tumor mutation burden (TMB) is reported as ""nan,"" how should we interpret this result when considering a potential response to Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has undergone a lymph node biopsy with transcriptomic profiling of the tumor immune microenvironment. Given that the tumor mutation burden (TMB) is reported as ""nan,"" how should we interpret this result when considering a potential response to Atezolizumab therapy? Conduct a detailed gene expression analysis on the tumor sample, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use validated techniques that adhere to current clinical guidelines and are supported by the latest peer-reviewed research.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ee3844-ar-ee3844c.pkl. "
BLCA,1.0,0.039215686,inflamed,NR,"A  white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment from a lung biopsy and a tumor mutational burden of 1.0. Based on these findings, how likely is he to respond to Atezolizumab therapy?","A  white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment from a lung biopsy and a tumor mutational burden of 1.0. Based on these findings, how likely is he to respond to Atezolizumab therapy? Please perform an in-depth analysis of the tumor's gene expression, concentrating on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that you utilize clinically validated methods that comply with current guidelines and are supported by recent peer-reviewed research.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ef0e3d-ar-ef0e3d2.pkl. "
BLCA,14.0,,desert,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. His tumor immune microenvironment was profiled using transcriptomic analysis from a ureter biopsy, and his TMB is 14.0 mutations per megabase. Based on these findings, how likely is he to respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. His tumor immune microenvironment was profiled using transcriptomic analysis from a ureter biopsy, and his TMB is 14.0 mutations per megabase. Based on these findings, how likely is he to respond to Atezolizumab therapy? Please conduct a comprehensive gene expression analysis of the tumor, paying special attention to markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that you apply clinically validated techniques that align with current guidelines and are substantiated by recent peer-reviewed research.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eff2ce-ar-eff2ce3.pkl. "
BLCA,14.0,1.098039216,inflamed,NR,I have a white male patient with bladder urothelial carcinoma (BLCA) whose kidney biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden (TMB) of 14.0. Could this patient potentially benefit from Atezolizumab therapy?,"I have a white male patient with bladder urothelial carcinoma (BLCA) whose kidney biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden (TMB) of 14.0. Could this patient potentially benefit from Atezolizumab therapy? Please perform a detailed gene expression profiling of the tumor, with a particular focus on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use methods that are clinically validated, adhere to current guidelines, and are supported by the latest peer-reviewed research.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f20b82-ar-f20b827.pkl. "
BLCA,9.0,,excluded,R,"In a Black or African American patient with bladder urothelial carcinoma, who has a tumor mutation burden of 9.0 and available transcriptomic data of the tumor immune microenvironment from a bladder biopsy, would we expect a favorable response to atezolizumab therapy?","In a Black or African American patient with bladder urothelial carcinoma, who has a tumor mutation burden of 9.0 and available transcriptomic data of the tumor immune microenvironment from a bladder biopsy, would we expect a favorable response to atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor tissue, with special emphasis on identifying markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that you use clinically validated methods in accordance with current guidelines and that these methods are supported by the latest peer-reviewed research.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f275eb-ar-f275eb8.pkl. "
BLCA,8.0,,desert,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 8.0 and whose bladder biopsy provides a transcriptomic profile of the tumor immune microenvironment, what is the likelihood of a favorable response to atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 8.0 and whose bladder biopsy provides a transcriptomic profile of the tumor immune microenvironment, what is the likelihood of a favorable response to atezolizumab therapy? Please conduct a detailed gene expression profiling of the tumor tissue, focusing specifically on markers that indicate the presence of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that you utilize clinically validated methods that comply with current guidelines and are supported by the latest peer-reviewed research.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f28c01-ar-f28c015.pkl. "
BLCA,7.0,0.803921569,desert,NR,"For a Caucasian female patient with bladder urothelial carcinoma, a tumor mutational burden of 7.0, and a transcriptomic profile of her tumor immune microenvironment obtained from a bladder biopsy, how likely is it that she will respond favorably to Atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma, a tumor mutational burden of 7.0, and a transcriptomic profile of her tumor immune microenvironment obtained from a bladder biopsy, how likely is it that she will respond favorably to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor tissue, specifically targeting markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use established, clinically validated methods that adhere to current guidelines and are supported by the latest peer-reviewed research.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f2aae1-ar-f2aae14.pkl. "
BLCA,4.0,,excluded,NR,"I have an Asian female patient with bladder urothelial carcinoma who has undergone a kidney biopsy providing a transcriptomic profile of the tumor immune microenvironment. Given her tumor mutation burden of 4.0, what is the likelihood that she will respond to atezolizumab therapy?","I have an Asian female patient with bladder urothelial carcinoma who has undergone a kidney biopsy providing a transcriptomic profile of the tumor immune microenvironment. Given her tumor mutation burden of 4.0, what is the likelihood that she will respond to atezolizumab therapy? Please conduct a detailed gene expression analysis on the tumor tissue. In your analysis, include markers that indicate the presence of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use clinically validated techniques that comply with current guidelines and are supported by the latest peer-reviewed studies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f3a9bc-ar-f3a9bce.pkl. "
BLCA,7.0,0.529411765,desert,NR,"We have a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of his tumor immune microenvironment from a kidney biopsy. Given that his tumor mutational burden is 7.0 mutations per megabase, can we predict his likelihood of responding to Atezolizumab therapy?","We have a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of his tumor immune microenvironment from a kidney biopsy. Given that his tumor mutational burden is 7.0 mutations per megabase, can we predict his likelihood of responding to Atezolizumab therapy? Please perform a comprehensive gene expression analysis on the tumor specimen. Ensure that your evaluation includes specific markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use clinically validated methods that align with current guidelines and have been supported by recent peer-reviewed studies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f82bbd-ar-f82bbdc.pkl. "
BLCA,,5.921568627,inflamed,R,"In a Caucasian male patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the TMB is reported as nan. Can we accurately predict his response to Atezolizumab based on these findings?","In a Caucasian male patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the TMB is reported as nan. Can we accurately predict his response to Atezolizumab based on these findings? Please conduct a detailed gene expression analysis on the tumor specimen. Be sure to include assessment of markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use clinically validated techniques that adhere to current guidelines and are corroborated by recent peer-reviewed research.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fb7aec-ar-fb7aec7.pkl. "
BLCA,5.0,,desert,NR,"A white male patient with bladder urothelial carcinoma has undergone a bladder biopsy yielding transcriptomic profiling of the tumor immune microenvironment, with a tumor mutation burden of 5.0. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has undergone a bladder biopsy yielding transcriptomic profiling of the tumor immune microenvironment, with a tumor mutation burden of 5.0. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy? Please perform a comprehensive gene expression profiling of the tumor specimen. Ensure that your analysis specifically evaluates markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Utilize clinically validated methods that conform to current guidelines and are supported by recent peer-reviewed research.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fd9476-ar-fd94761.pkl. "
BLCA,7.0,0.352941176,desert,NR,"I have a Caucasian patient with bladder urothelial carcinoma (BLCA) whose bladder biopsy revealed a detailed transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden (TMB) of 7.0. Based on these findings, is this patient likely to respond favorably to Atezolizumab therapy?","I have a Caucasian patient with bladder urothelial carcinoma (BLCA) whose bladder biopsy revealed a detailed transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden (TMB) of 7.0. Based on these findings, is this patient likely to respond favorably to Atezolizumab therapy? Kindly conduct a comprehensive gene expression analysis on the tumor sample. In your evaluation, please include specific markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Ensure that you use clinically validated techniques that align with current guidelines and are supported by the latest peer-reviewed evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fed609-ar-fed6099.pkl. "
BLCA,10.0,,desert,R,"For a white male patient with bladder urothelial carcinoma, a tumor mutation burden of 10.0, and transcriptomic data from the tumor immune microenvironment, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, a tumor mutation burden of 10.0, and transcriptomic data from the tumor immune microenvironment, what is the likelihood of a favorable response to Atezolizumab therapy? Please perform a detailed gene expression profiling of the tumor specimen. The analysis should specifically assess biomarkers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use clinically validated methods that adhere to current best-practice guidelines and are supported by up-to-date peer-reviewed research.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ffa5c7-ar-ffa5c7c.pkl. "
